<!DOCTYPE html><html lang="en-GB"><head><meta charSet="utf-8"/><meta http-equiv="x-ua-compatible" content="ie=edge"/><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"/><style data-href="/component---src-templates-chapter-level-2-chapter-level-2-tsx.d09ef71dfbb262c31a03.css" id="gatsby-global-css">.page-header{margin:0 0 3rem}.page-header__pre-heading{font-size:1.125rem;line-height:1.5rem;display:block;margin:0}.page-header__heading{font-size:2.75rem;line-height:3.5rem;margin:0 0 .5rem}.page-header__lead{font-size:1.25rem;line-height:1.75rem;margin:0 0 .5rem}.page-header__cta{font-size:1rem;line-height:1.5rem;display:block;margin:0}@media print{.page-header__cta{display:none!important}}.breadcrumbs{font-size:1rem;line-height:1.5rem;list-style:none;margin:.5em 0 2em;max-width:100%;padding:0}@media print{.breadcrumbs{display:none!important}}.breadcrumbs__crumb{display:inline-block}.breadcrumbs__crumb:before{content:">";font-size:80%;margin:0 .25em}.breadcrumbs__crumb:first-child:before{display:none}.breadcrumbs a{color:#222;text-decoration:underline}.breadcrumbs a:hover{text-decoration:none}.breadcrumbs a:focus{color:#005ea5}.breadcrumbs a:active{color:#222}.OldIEMessage-module--container--2Z9pT{max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);margin:auto auto 1rem}.OldIEMessage-module--alert--3CB3M{background:#ffdfa4;border:1px solid #966f2f;margin:1rem auto 0;max-width:73.125rem;padding:1rem}.OldIEMessage-module--alert--3CB3M a{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.OldIEMessage-module--alert--3CB3M a:visited{color:#4c2c92}.OldIEMessage-module--alert--3CB3M a:hover{color:#2e8aca}.OldIEMessage-module--alert--3CB3M a:focus{outline:.25rem solid #0092a6;color:#005ea5}.OldIEMessage-module--alert--3CB3M a:active{color:#222}.OldIEMessage-module--alert--3CB3M h2{margin-top:0}.OldIEMessage-module--alert--3CB3M h2,.OldIEMessage-module--alert--3CB3M p{max-width:600px}.OldIEMessage-module--lastP---CQws{margin-bottom:0}.CoronaMessage-module--wrapper--zRiaV{background:#ffeb3b;padding:.5rem 0}.CoronaMessage-module--wrapper--zRiaV p{margin-top:0}.CoronaMessage-module--wrapper--zRiaV a{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.CoronaMessage-module--wrapper--zRiaV a:visited{color:#4c2c92}.CoronaMessage-module--wrapper--zRiaV a:hover{color:#2e8aca}.CoronaMessage-module--wrapper--zRiaV a:focus{outline:.25rem solid #0092a6;color:#005ea5}.CoronaMessage-module--wrapper--zRiaV a:active{color:#222}@media print{.CoronaMessage-module--wrapper--zRiaV{display:none}}.CoronaMessage-module--container--36Biz{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem)}.CoronaMessage-module--container--36Biz>:last-child{margin-bottom:0}.SubNav-module--wrapper--yAXWY{background:#fff;color:#000;display:block}.SubNav-module--list--1K9bK{margin:0;padding:0}.SubNav-module--list--1K9bK li{list-style:none;margin:0}.SubNav-module--link--39i23{border-color:#004650;border-style:solid;border-width:0 .25rem;color:#222;display:block;font-weight:400;padding:.5rem 1rem .5rem 2rem;text-decoration:none}.SubNav-module--link--39i23:focus{color:#222;outline:.25rem solid #0092a6;outline-offset:-.5rem}.SubNav-module--link--39i23:active,.SubNav-module--link--39i23:hover,.SubNav-module--link--39i23:visited{border-color:#004650;border-style:solid;border-width:0 .25rem;color:#222}.SubNav-module--link--39i23:hover{background:#d6d6d6;color:#222;text-decoration:underline}.SubNav-module--imageLink--3xwIS{display:none}@media(min-width:56.25em){.SubNav-module--wrapper--yAXWY{border-bottom:.125rem solid #004650;bottom:0;height:3rem;left:0;position:absolute;width:100%}.SubNav-module--imageLink--3xwIS{display:inline-block}.SubNav-module--list--1K9bK{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);height:100%}.SubNav-module--list--1K9bK li{display:inline-block;height:100%;vertical-align:middle}.SubNav-module--link--39i23{border:0;display:block;height:100%;padding:0 1rem}.SubNav-module--link--39i23[aria-current=page],.SubNav-module--link--39i23[aria-current=true]{background:transparent}.SubNav-module--link--39i23[aria-current=page]:after,.SubNav-module--link--39i23[aria-current=true]:after{display:none}.SubNav-module--link--39i23:before{content:"";display:inline-block;height:100%;vertical-align:middle}.SubNav-module--link--39i23:active,.SubNav-module--link--39i23:hover,.SubNav-module--link--39i23:visited{border:0}}.SubNav-module--image--uq-a2{height:100%}.Nav-module--link--3JzDA .Nav-module--tooltip--1Uj-W{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.Nav-module--link--3JzDA:focus-visible .Nav-module--tooltip--1Uj-W{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;outline:1px solid #0092a6;overflow:visible;padding:0 .25rem;position:absolute;width:auto;z-index:1}.Nav-module--visuallyHidden--ORHqX{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.Nav-module--wrapper--2_xng{display:none;position:relative}@media print{.Nav-module--wrapper--2_xng{display:none!important}}@media(min-width:56.25em){.Nav-module--wrapper--2_xng{display:block}}.Nav-module--wrapperExpanded--3RxQB{display:block}.Nav-module--nav--2aQpa abbr[title]{border-bottom:0;cursor:help;text-decoration:none}.Nav-module--myAccount--3lsif{border-top:1px solid #fff}@media(min-width:56.25em){.Nav-module--myAccount--3lsif{display:none}}.Nav-module--myAccountHeading--1A5_B{border:.25rem solid #004650;font-size:100%;margin:0;padding:.5rem 1rem}.Nav-module--menuWrapper--2fp8S{background:#004650;color:#fff;padding:.25rem 0}.Nav-module--menuList--264L-{list-style:none;margin:auto;padding:0}.Nav-module--menuList--264L->li{margin:0}a.Nav-module--link--3JzDA{border-color:#004650;border-style:solid;border-width:0 .25rem;color:#fff;display:block;font-weight:400;padding:.5rem 1rem;text-decoration:none}a.Nav-module--link--3JzDA span{text-decoration:inherit}a.Nav-module--link--3JzDA:focus{color:#fff;outline:.25rem solid #fff;outline-offset:-.5rem;z-index:1}a.Nav-module--link--3JzDA:visited{color:#fff}a.Nav-module--link--3JzDA:active{background:#acadad;color:#222}a.Nav-module--link--3JzDA:hover{background:#d6d6d6;color:#222;text-decoration:underline}a.Nav-module--link--3JzDA[aria-current=page],a.Nav-module--link--3JzDA[aria-current=true]{background:#fff;color:#222;font-weight:700}a.Nav-module--link--3JzDA[aria-current=page]:focus,a.Nav-module--link--3JzDA[aria-current=true]:focus{outline-color:#0092a6;outline-offset:-.25rem}@media(min-width:56.25em){.Nav-module--wrapperWithSubLinks--3PUfX{padding-bottom:3rem}.Nav-module--menuList--264L-{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);display:-webkit-flex;display:flex;-webkit-flex-direction:row;flex-direction:row;-webkit-flex-wrap:nowrap;flex-wrap:nowrap;-webkit-justify-content:space-between;justify-content:space-between}.Nav-module--menuList--264L->li{-webkit-flex-grow:1;flex-grow:1}a.Nav-module--link--3JzDA{border-left-width:0;border-right-width:0;display:-webkit-flex;display:flex;-webkit-flex-direction:column;flex-direction:column;height:100%;-webkit-justify-content:center;justify-content:center;line-height:1.25;margin:0;padding:.5rem;position:relative;text-align:center}a.Nav-module--link--3JzDA:focus{outline-offset:-.25rem}a.Nav-module--link--3JzDA span{display:inline-block;vertical-align:middle;white-space:normal}a.Nav-module--link--3JzDA[aria-current=page],a.Nav-module--link--3JzDA[aria-current=true]{margin:0 .25rem}a.Nav-module--link--3JzDA[aria-current=page]:focus,a.Nav-module--link--3JzDA[aria-current=true]:focus{outline-offset:-.5rem}a.Nav-module--link--3JzDA[aria-current=page]:after,a.Nav-module--link--3JzDA[aria-current=true]:after{background:#fff;content:"";display:block;height:.25rem;left:0;position:absolute;top:100%;width:100%}a.Nav-module--link--3JzDA[aria-current=page]:hover:after,a.Nav-module--link--3JzDA[aria-current=true]:hover:after{background:#d6d6d6}}@media(min-width:56.25em)and (min-width:75em){a.Nav-module--link--3JzDA{padding:1rem}}.Autocomplete-module--ac--2PqiF .autocomplete__wrapper{position:relative}.Autocomplete-module--ac--2PqiF .autocomplete__hint,.Autocomplete-module--ac--2PqiF .autocomplete__input{-webkit-appearance:none;border:1px solid #222;border-radius:0;box-sizing:border-box;margin-bottom:0;width:100%}.Autocomplete-module--ac--2PqiF .autocomplete__input{background-color:#e9e9e9!important;height:2.5rem!important;margin:0!important;max-width:100%!important;position:relative;z-index:101}.Autocomplete-module--ac--2PqiF .autocomplete__input:focus{outline:3px solid #0092a6;outline-offset:-3px;z-index:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::-webkit-input-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::-moz-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input:-ms-input-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::-ms-input-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__hint{color:#bfc1c3;position:absolute}.Autocomplete-module--ac--2PqiF .autocomplete__input--default{padding:.5rem}.Autocomplete-module--ac--2PqiF .autocomplete__input--focused{outline:3px solid #0092a6;outline-offset:-3px}.Autocomplete-module--ac--2PqiF .autocomplete__input--show-all-values{padding:4px 34px 4px 4px;cursor:pointer}.Autocomplete-module--ac--2PqiF .autocomplete__dropdown-arrow-down{z-index:-1;display:inline-block;position:absolute;right:8px;width:24px;height:24px;top:10px}.Autocomplete-module--ac--2PqiF .autocomplete__menu{background-color:#fff;border:1px solid #d6d6d6;border-top:0;color:#34384b;margin:0;max-width:100%;padding:0;text-align:left;width:-webkit-calc(100vw - 2rem);width:calc(100vw - 2rem)}@media(min-width:37.5em){.Autocomplete-module--ac--2PqiF .autocomplete__menu{width:100%}}.Autocomplete-module--ac--2PqiF .autocomplete__menu--visible{display:block}.Autocomplete-module--ac--2PqiF .autocomplete__menu--hidden{display:none}.Autocomplete-module--ac--2PqiF .autocomplete__menu--overlay{box-shadow:0 .25rem 1rem .25rem rgba(0,0,0,.1);left:0;position:absolute;top:100%;z-index:100}.Autocomplete-module--ac--2PqiF .autocomplete__menu--inline{position:relative}.Autocomplete-module--ac--2PqiF .autocomplete__option{border-left-width:0;border-bottom:1px solid #d6d6d6;border-right-width:0;border-top-width:1px;color:#005ea5;cursor:pointer;display:block;margin:0;position:relative}.Autocomplete-module--ac--2PqiF .autocomplete__option a{color:inherit;display:block;font-weight:400;padding:.5rem;text-decoration:none}.Autocomplete-module--ac--2PqiF .autocomplete__option mark{background:0;color:inherit;font-weight:700;padding:0}.Autocomplete-module--ac--2PqiF .autocomplete__option>*{pointer-events:none}.Autocomplete-module--ac--2PqiF .autocomplete__option:first-of-type{border-top-width:0}.Autocomplete-module--ac--2PqiF .autocomplete__option:last-of-type{border-bottom-width:0}.Autocomplete-module--ac--2PqiF .autocomplete__option--odd{background-color:#fafafa}.Autocomplete-module--ac--2PqiF .autocomplete__option--focused,.Autocomplete-module--ac--2PqiF .autocomplete__option:hover{background-color:#e9e9e9;color:#005ea5;outline:none;text-decoration:underline}.Autocomplete-module--ac--2PqiF .autocomplete__option--no-results{background-color:#fafafa;color:#646b6f;cursor:not-allowed}.Autocomplete-module--ac--2PqiF .autocomplete__hint,.Autocomplete-module--ac--2PqiF .autocomplete__input,.Autocomplete-module--ac--2PqiF .autocomplete__option{font-size:16px;line-height:1.25}.Search-module--search--2wNll{margin:0;padding-right:2.5rem;position:relative}.Search-module--label--1rrog{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute!important;width:1px}.Search-module--button--2FbnI{background:#393939;border:0;color:#fff;cursor:pointer;height:2.5rem;min-width:2.5rem;padding:0 .5rem;position:absolute;right:0;text-align:center;top:0;z-index:101}.Search-module--button--2FbnI:focus{outline:.25rem solid #0092a6}.Search-module--button--2FbnI .Search-module--icon--2JB42{font-size:150%;vertical-align:middle}.Account-module--account--1BtRh{position:relative}.Account-module--button--zZii1{background:#fff;border:1px solid #222;color:#222;cursor:pointer;display:inline-block;font-family:inherit;font-size:inherit;font-weight:400;height:2.5rem;line-height:2.5rem;padding:0 .5rem;text-decoration:none;vertical-align:middle;white-space:nowrap}.Account-module--button--zZii1:focus{outline:.25rem solid #0092a6}.Account-module--button--zZii1:visited{color:#222}.Account-module--button--zZii1:hover{border:1px solid #222}.Account-module--myAccount--3jTaq:after{border-left:.25rem solid transparent;border-right:.25rem solid transparent;border-top:.5rem solid #393939;content:"";display:inline-block;height:0;margin-left:.5rem;vertical-align:middle;width:0}.Account-module--myAccount--3jTaq[aria-expanded=true]:after{border-bottom:.5rem solid #222;border-top:0}.Account-module--menu--3C46i{background:#fff;border:1px solid #393939;list-style:none;margin:.625rem 0 0;padding:0;position:absolute;right:0;top:100%;z-index:2}.Account-module--menu--3C46i:focus{outline:.25rem solid #0092a6}.Account-module--menu--3C46i[aria-hidden=true]{display:none}.Account-module--menu--3C46i:before{border-bottom:.5rem solid #393939;border-left:.25rem solid transparent;border-right:.25rem solid transparent}.Account-module--menu--3C46i:after,.Account-module--menu--3C46i:before{bottom:100%;content:"";display:block;height:0;position:absolute;right:1rem;width:0}.Account-module--menu--3C46i:after{border-bottom:.4rem solid #fff;border-left:.2rem solid transparent;border-right:.2rem solid transparent;margin-right:1px}.Account-module--menu--3C46i li{border-top:1px solid #d6d6d6;list-style:none;margin:0}.Account-module--menu--3C46i a{color:#005ea5;display:block;padding:.5rem 1rem;text-decoration:none;white-space:nowrap}.Account-module--menu--3C46i a:focus{outline:.25rem solid #0092a6}.Account-module--menu--3C46i a:hover{background:#e9e9e9;text-decoration:underline}.Header-module--header--3os44{background:#fff;border-bottom:.125rem solid #004650;box-sizing:border-box;font-family:Lato,Helvetica Neue,Helvetica,Arial,sans-serif}.Header-module--header--3os44 *,.Header-module--header--3os44 :after,.Header-module--header--3os44 :before{box-sizing:inherit;font-family:inherit}@media print{.Header-module--header--3os44{border-bottom:none}}.Header-module--container--1mfIr{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);padding:1rem 0 0}.Header-module--container--1mfIr:after{clear:both;content:"";display:table}.Header-module--home--1TCPb{color:#000;display:inline-block;float:left;height:1.875rem;margin-bottom:1rem}@media print{.Header-module--home--1TCPb:after{content:none!important}}.Header-module--home--1TCPb:focus{outline:.25rem solid #0092a6}.Header-module--home--1TCPb:visited{color:#000}.Header-module--home--1TCPb .Header-module--icon--4LSt5{height:100%;width:auto}.Header-module--wrapper--2e13D{display:-webkit-flex;display:flex;-webkit-flex-grow:1;flex-grow:1;float:right;-webkit-justify-content:space-between;justify-content:space-between;margin-bottom:1rem;width:50%}@media print{.Header-module--wrapper--2e13D{display:none!important}}.Header-module--wrapper--2e13D:after{clear:both;content:"";display:table}.Header-module--search--2nfnz{-webkit-flex-grow:1;flex-grow:1;float:left;margin-right:1rem;min-width:66.6666666667%}.Header-module--mobileMenuBtn--1LgyL{-webkit-appearance:none;-moz-appearance:none;appearance:none;background:none;border:1px solid #222;float:right;font-family:inherit;font-size:110%;height:2.5rem;min-width:4.6875rem;white-space:nowrap}.Header-module--mobileMenuBtn--1LgyL:after{border-left:.25rem solid transparent;border-right:.25rem solid transparent;border-top:.5rem solid #393939;content:"";display:inline-block;height:0;margin-left:.5rem;vertical-align:middle;width:0}.Header-module--mobileMenuBtn--1LgyL[aria-expanded=true]:after{border-bottom:.5rem solid #222;border-top:0}.Header-module--account--y72Q4{display:none}@media(max-width:56.24em){.Header-module--home--1TCPb{float:none}.Header-module--wrapper--2e13D{float:none;width:auto}}@media(min-width:56.25em){.Header-module--header--3os44{border-bottom:.25rem solid #fff}.Header-module--container--1mfIr{display:-webkit-flex;display:flex;-webkit-justify-content:space-between;justify-content:space-between}.Header-module--home--1TCPb{height:2.5rem;margin-right:2rem}.Header-module--wrapper--2e13D{-webkit-justify-content:flex-end;justify-content:flex-end}.Header-module--search--2nfnz{margin-right:2rem}.Header-module--mobileMenuBtn--1LgyL{display:none}.Header-module--account--y72Q4{display:block}}.SkipLinks-module--list--1WwLa{list-style:none;margin:0;padding:0}@media print{.SkipLinks-module--list--1WwLa{display:none!important}}.SkipLinks-module--list--1WwLa li{list-style:none;margin:0}.SkipLinks-module--link--hkZw8{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.SkipLinks-module--link--hkZw8:focus{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;left:.25rem;outline:3px solid #0092a6;overflow:visible;padding:.5rem 1rem;position:absolute;top:.25rem;white-space:nowrap;width:auto;z-index:1}.Social-module--wrapper--2nKsd{clear:left}.Social-module--list--E5R5J{list-style:none;margin:0;max-width:100%;padding:0}.Social-module--list--E5R5J li{margin:0 0 .25rem}.Social-module--list--E5R5J svg{margin:-.125rem .25rem 0 0;vertical-align:middle}@media(min-width:37.5em){.Social-module--list--E5R5J li{float:left;margin:0 1rem 0 0}}@media(min-width:56.25em){.Social-module--wrapper--2nKsd{clear:none}.Social-module--wrapper--2nKsd li{float:none;margin:0 0 .25rem}}.Legal-module--wrapper--3AYMO{font-size:.875rem;line-height:1.25rem;background:#393939;padding:1rem 0}.Legal-module--wrapper--3AYMO a{text-decoration:underline}.Legal-module--container--3TTBh{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem)}.Legal-module--menu--1e1Iy{margin:0 0 1rem}@media print{.Legal-module--menu--1e1Iy{display:none!important}}.Legal-module--menu--1e1Iy ul{list-style:none;margin:0;max-width:100%;padding:0}.Legal-module--menu--1e1Iy li{margin:0}.Legal-module--menu--1e1Iy a{display:block}.Legal-module--copyright--34nsI{font-size:.875rem;line-height:1.25rem;margin:0}@media print{.Legal-module--copyright--34nsI{float:none!important;max-width:100%}}@media(min-width:37.5em){.Legal-module--menu--1e1Iy li{display:inline-block;margin-right:1rem}}@media(min-width:75em){.Legal-module--wrapper--3AYMO:after,.Legal-module--wrapper--3AYMO:before{content:" ";display:table}.Legal-module--wrapper--3AYMO:after{clear:both}.Legal-module--menu--1e1Iy{float:left;margin:0}.Legal-module--copyright--34nsI{float:right}}.Services-module--link--2y_1q .Services-module--tooltip--pg3nW{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.Services-module--link--2y_1q:focus-visible .Services-module--tooltip--pg3nW{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;outline:1px solid #0092a6;overflow:visible;padding:0 .25rem;position:absolute;width:auto;z-index:1}.Services-module--visuallyHidden--t9mfm{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.Services-module--wrapper--2qOoE{margin:0 0 2rem}.Services-module--list--3SZQu{list-style:none;margin:0;padding:0}.Services-module--list--3SZQu li{margin:0 0 .25rem}@media(min-width:37.5em){.Services-module--wrapper--2qOoE{border-right:2px solid #393939;float:left;width:33.3333333333%}}@media(min-width:56.25em){.Services-module--wrapper--2qOoE{border-right:2px solid #393939;float:left;margin:0;width:25%}}.Pages-module--wrapper--30REl{margin:0 0 2rem}.Pages-module--list--vvSk4{list-style:none;margin:0;padding:0}.Pages-module--list--vvSk4 li{margin:0 0 .25rem}@media(min-width:25em){.Pages-module--list--vvSk4{-webkit-column-count:2;-moz-column-count:2;column-count:2;-webkit-column-gap:1rem;-moz-column-gap:1rem;column-gap:1rem}}@media(min-width:37.5em){.Pages-module--wrapper--30REl{float:left;margin:0;padding:0 0 0 2rem;width:66.6666666667%}}@media(min-width:56.25em){.Pages-module--wrapper--30REl{float:left;margin:0;padding:0 2rem;width:50%}.Pages-module--list--vvSk4{-webkit-column-count:2;-moz-column-count:2;column-count:2;-webkit-column-gap:1rem;-moz-column-gap:1rem;column-gap:1rem}}.Footer-module--link--CGIYk .Footer-module--tooltip--1zoJv{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.Footer-module--link--CGIYk:focus-visible .Footer-module--tooltip--1zoJv{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;outline:1px solid #0092a6;overflow:visible;padding:0 .25rem;position:absolute;width:auto;z-index:1}.Footer-module--visuallyHidden--3CCnP{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.Footer-module--footer--2QrGZ{background:#222;box-sizing:border-box;color:#fff;contain-intrinsic-size:350px;content-visibility:auto;font-family:Lato,Helvetica Neue,Helvetica,Arial,sans-serif;margin:2rem 0 0}.Footer-module--footer--2QrGZ a{color:#fff;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.Footer-module--footer--2QrGZ a:visited{color:#fff}.Footer-module--footer--2QrGZ a:hover{color:#d6d6d6}.Footer-module--footer--2QrGZ a:focus{outline:.25rem solid #fff;color:#fff}.Footer-module--footer--2QrGZ a:active{color:#d6d6d6}.Footer-module--footer--2QrGZ *,.Footer-module--footer--2QrGZ :after,.Footer-module--footer--2QrGZ :before{box-sizing:inherit}.Footer-module--footer--2QrGZ a{font-weight:400}.Footer-module--container--1iuoB{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);padding:1rem 0}.Footer-module--container--1iuoB:after,.Footer-module--container--1iuoB:before{content:" ";display:table}.Footer-module--container--1iuoB:after{clear:both}@media print{.Footer-module--container--1iuoB{display:none!important}}.Footer-module--logo--3DGKv{display:block;height:0;margin:0 0 2rem;padding:0 0 29.0496453901px;position:relative;width:80px}.Footer-module--logo--3DGKv svg{display:block;height:100%!important;left:0;position:absolute;top:0;width:100%!important}@media(min-width:56.25em){.Footer-module--logo--3DGKv{margin-bottom:1rem}}.BackToTop-module--wrapper--2Z0EU{margin-top:3rem}@media print{.BackToTop-module--wrapper--2Z0EU{display:none}}.BackToTop-module--nav--1DPZ6{background:#e9e9e9;border-top:1px solid #adadad;width:100%;z-index:1}.BackToTop-module--anchor--1Nia6{display:block;line-height:1rem;padding:1rem 0}.BackToTop-module--anchor--1Nia6:visited{color:#005ea5}.BackToTop-module--anchor--1Nia6 svg{-webkit-transition:all .25s ease;transition:all .25s ease}.BackToTop-module--anchor--1Nia6:hover{background:#f4f4f4}.BackToTop-module--anchor--1Nia6:hover svg{-webkit-transform:translateY(-.125rem);transform:translateY(-.125rem)}@supports((position:-webkit-sticky) or (position:sticky)){.BackToTop-module--wrapper--2Z0EU{bottom:0;left:0;margin:0;pointer-events:none;position:absolute;right:0;top:min(100vh,-webkit-calc(100% - 3rem));top:min(100vh,calc(100% - 3rem));width:100%;z-index:99}.BackToTop-module--nav--1DPZ6{position:-webkit-sticky;position:sticky;pointer-events:all;top:-webkit-calc(100vh - 3rem);top:calc(100vh - 3rem);background:#e9e9e9;border-top:1px solid #adadad;width:100%;z-index:1}}@font-face{font-display:optional;font-family:Lato;font-style:normal;font-weight:400;src:local("Lato"),url(../../../../fonts/lato-v17-latin-regular.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-regular.woff) format("woff")}@font-face{font-display:optional;font-family:Lato;font-style:italic;font-weight:400;src:local("Lato"),url(../../../../fonts/lato-v17-latin-italic.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-italic.woff) format("woff")}@font-face{font-display:optional;font-family:Lato;font-style:normal;font-weight:700;src:local("Lato"),url(../../../../fonts/lato-v17-latin-700.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-700.woff) format("woff")}@font-face{font-display:optional;font-family:Lato;font-style:normal;font-weight:900;src:local("Lato"),url(../../../../fonts/lato-v17-latin-900.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-900.woff) format("woff")}/*! normalize.css v8.0.1 | MIT License | github.com/necolas/normalize.css */html{line-height:1.15;-webkit-text-size-adjust:100%}body{margin:0}main{display:block}h1{font-size:2em;margin:.67em 0}hr{box-sizing:content-box;height:0;overflow:visible}pre{font-family:monospace,monospace;font-size:1em}a{background-color:transparent}abbr[title]{border-bottom:none;text-decoration:underline;-webkit-text-decoration:underline dotted;text-decoration:underline dotted}b,strong{font-weight:bolder}code,kbd,samp{font-family:monospace,monospace;font-size:1em}small{font-size:80%}sub,sup{font-size:75%;line-height:0;position:relative;vertical-align:baseline}sub{bottom:-.25em}sup{top:-.5em}img{border-style:none}button,input,optgroup,select,textarea{font-family:inherit;font-size:100%;line-height:1.15;margin:0}button,input{overflow:visible}button,select{text-transform:none}[type=button],[type=reset],[type=submit],button{-webkit-appearance:button}[type=button]::-moz-focus-inner,[type=reset]::-moz-focus-inner,[type=submit]::-moz-focus-inner,button::-moz-focus-inner{border-style:none;padding:0}[type=button]:-moz-focusring,[type=reset]:-moz-focusring,[type=submit]:-moz-focusring,button:-moz-focusring{outline:1px dotted ButtonText}fieldset{padding:.35em .75em .625em}legend{box-sizing:border-box;color:inherit;display:table;max-width:100%;padding:0;white-space:normal}progress{vertical-align:baseline}textarea{overflow:auto}[type=checkbox],[type=radio]{box-sizing:border-box;padding:0}[type=number]::-webkit-inner-spin-button,[type=number]::-webkit-outer-spin-button{height:auto}[type=search]{-webkit-appearance:textfield;outline-offset:-2px}[type=search]::-webkit-search-decoration{-webkit-appearance:none}::-webkit-file-upload-button{-webkit-appearance:button;font:inherit}details{display:block}summary{display:list-item}[hidden],template{display:none}.show-print{display:none!important}@media print{.show-print{display:block!important}}@media print{.hide-print{display:none!important}}@media print{.remove-appended-print-link:after{content:none!important}}@media print{*{background:transparent!important;box-shadow:none!important;color:#000!important;text-shadow:none!important}a,a:visited{text-decoration:underline}}@media print{h1 a:after,h2 a:after,h3 a:after,h4 a:after,h5 a:after,h6 a:after{content:none!important}}@media print{a[href]:after{content:" (" attr(href) ")"}}@media print{abbr[title]:after{content:" (" attr(title) ")"}}@media print{.ir a:after,a[href^="#"]:after,a[href^="javascript:"]:after{content:""}}@media print{blockquote,pre{border:1px solid #999;page-break-inside:avoid}}@media print{thead{display:table-header-group}}@media print{img,tr{page-break-inside:avoid}}@media print{img{max-width:100%!important}}@media print{img:not([alt]),img[alt=""]{display:none!important}}@media print{@page{margin:.5cm}}@media print{h2,h3,p{orphans:3;widows:3}}@media print{h2,h3{page-break-after:avoid}}.clearfix:after,.clearfix:before{content:" ";display:table}.clearfix:after{clear:both}.container{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem)}.container--full{max-width:100%;padding:0 2%;width:auto}html{box-sizing:border-box;font-size:.9375rem;overflow-x:hidden}html *,html :after,html :before{box-sizing:inherit}@media(min-width:56.25em){html{font-size:1.03125rem;font-size:-webkit-calc(.375rem + 1vw);font-size:calc(.375rem + 1vw)}}@media(min-width:75em){html{font-size:1.125rem}}body{background:#f4f4f4;color:#222;font-family:Lato,Helvetica Neue,Helvetica,Arial,sans-serif;font-style:normal;line-height:1.5rem;overflow-x:hidden;text-rendering:optimizelegibility}img{max-width:100%}hr{background:0;border:0;border-top:.0625em solid #adadad;margin:2em 0;padding:0}.p,p{font-size:1rem;line-height:1.5rem;font-feature-settings:"kern","onum","liga"}.lead,.p,p{margin-bottom:1rem;margin-top:1rem;font-weight:400;max-width:66ch}.lead{font-size:1.25rem;line-height:1.75rem}code{background:#e9e9e9;border:1px solid #adadad;border-radius:.125em;color:#222;display:inline-block;font-family:Monaco,Menlo,Consolas,Courier New,monospace;margin:0 0 .125em;padding:0 .25em}pre code{background:transparent;border:0;margin:0}.mark,mark{background-color:#fff999;padding:0 .25em}.small,small{font-size:85%}.h6,h6{font-size:1rem}.h5,.h6,h5,h6{line-height:1.5rem;margin-bottom:1rem;margin-top:1rem;clear:both;font-weight:700;max-width:66ch}.h5,h5{font-size:1.125rem}.h4,h4{font-size:1.25rem;line-height:1.75rem;margin-bottom:1rem;margin-top:1rem;clear:both;font-weight:700;max-width:66ch}.h3,h3{font-size:1.75rem;line-height:2rem}.h2,.h3,h2,h3{margin-bottom:1rem;margin-top:2rem;clear:both;font-weight:700;max-width:66ch}.h2,h2{font-size:2.25rem;line-height:2.5rem}.h1,.h2+.h3,.h2+h3,h1,h2+.h3,h2+h3{margin-top:0}.h1,h1{font-size:2.75rem;line-height:3.5rem;margin-bottom:1rem;clear:both;font-weight:900;max-width:66ch}.h1+.h2,.h1+h2,h1+.h2,h1+h2{margin-top:0}a{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}a:visited{color:#4c2c92}a:hover{color:#2e8aca}a:focus{outline:.25rem solid #0092a6;color:#005ea5}a:active{color:#222}.link--inverse{color:#fff;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.link--inverse:visited{color:#fff}.link--inverse:hover{color:#d6d6d6}.link--inverse:focus{outline:.25rem solid #fff;color:#fff}.link--inverse:active{color:#d6d6d6}.inverse-links a{color:#fff;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.inverse-links a:visited{color:#fff}.inverse-links a:hover{color:#d6d6d6}.inverse-links a:focus{outline:.25rem solid #fff;color:#fff}.inverse-links a:active{color:#d6d6d6}.list,ol,ul{font-feature-settings:"kern","onum","liga";margin-left:1rem;max-width:66ch;padding:0}.list--unstyled{list-style:none;margin-left:0;max-width:none;padding:0}.list--loose .list__item,.list--loose li{margin-bottom:.25rem}.list--piped{list-style:none;margin-left:0;padding:0}.list--piped .list__item,.list--piped li{display:inline-block;margin-right:-.25rem}.list--piped .list__item a,.list--piped li a{padding:.5rem}.list--piped .list__item:after,.list--piped li:after{border-left:1px solid #004650;content:"\200B";display:inline-block;margin:0 .5em;overflow:hidden;text-indent:-99px;vertical-align:middle;width:0}.list--piped .list__item:first-child a,.list--piped li:first-child a{padding-left:0}.list--piped .list__item:last-child:after,.list--piped li:last-child:after{display:none}.quote{font-size:1.25rem;line-height:1.75rem;border-left:.25em solid #004650;font-weight:400;margin:2rem 0;padding:0 0 0 4rem;position:relative}.quote:before{color:#004650;content:"\201C";display:block;font-family:Arial,sans-serif;font-size:5rem;font-weight:700;left:0;line-height:.8;position:absolute;text-align:center;top:0;width:4rem}@media print{.quote:before{color:#000}}.quote p{font-size:inherit}.quote cite,.quote footer{font-size:1rem;line-height:1.5rem;font-style:normal}table{background:#fff;border:1px solid #adadad;border-collapse:collapse;display:block;margin:0 0 1rem;max-width:100%;overflow-y:hidden;overflow-x:auto;width:100%!important}table th{vertical-align:bottom}table td{vertical-align:top}table td,table th{border:1px solid #adadad;padding:.5rem;text-align:left}table td:first-child,table th:first-child{border-left:0}table td:last-child,table th:last-child{border-right:0}table td p,table th p{margin-top:0}table :not(thead)+tbody tr:first-child th,table tbody tr:first-child th,table thead tr:first-child th{border-top:0}table tbody tr:last-child td{border-bottom:0}table tbody tr:nth-child(2n)>td{background-color:#e9e9e9}html{overflow-x:visible;scroll-behavior:smooth}@media(prefers-reduced-motion){html{scroll-behavior:auto}}body{font-family:Lato,Trebuchet MS,Roboto,Helvetica Neue,Helvetica,Arial,sans-serif;position:relative}.visually-hidden{position:absolute;overflow:hidden;clip:rect(0 0 0 0);height:1px;width:1px;margin:-1px;padding:0;border:0}#content-start:focus{outline:none}footer{margin-top:0!important}@supports((position:-webkit-sticky) or (position:sticky)){.Layout-module--main--1OIFf{position:relative;padding-bottom:4rem}}.stacked-nav{background:#fff;border:1px solid #adadad;margin:0 0 2em}@media print{.stacked-nav{display:none!important}}.stacked-nav__root{font-size:1rem;line-height:1.5rem;border-bottom:1px solid #adadad;font-weight:700;margin:0;max-width:none;position:relative;text-decoration:none}.stacked-nav__root a{color:#222}.stacked-nav__root--no-link{padding:.5em}.stacked-nav__hint{color:#222;display:block}.stacked-nav__hint :active{color:#fff}.stacked-nav__list{list-style:none;margin:0;max-width:100%;padding:0}.stacked-nav__list-item{border-top:1px solid #adadad}.stacked-nav__content-wrapper{display:block}.stacked-nav a{color:#005ea5;display:block;padding:.5em;position:relative;text-decoration:none}.stacked-nav a[aria-current=page],.stacked-nav a[aria-current=true]{background:#e9e9e9;font-weight:700}.stacked-nav a[aria-current=page]:before,.stacked-nav a[aria-current=true]:before{background:#004650;content:"";display:block;height:100%;left:0;position:absolute;top:0;width:.25em}.stacked-nav a:hover{background:#d6d6d6}.stacked-nav a:active{background:#004650;color:#fff}.stacked-nav a:active span{color:#fff}.stacked-nav__nested{list-style:none;margin:0;padding:0}.stacked-nav__nested .stacked-nav__content-wrapper{padding-left:1rem!important}.stacked-nav__nested ul .stacked-nav__content-wrapper{padding-left:2rem!important}.TopicChaptersMenu-module--toggleButton--2MGXA{-webkit-appearance:none;-moz-appearance:none;appearance:none;background:#e9e9e9;border:1px solid #adadad;color:#005ea5;cursor:pointer;display:block;margin:0 0 2rem;padding:1rem 2rem 1rem .5rem;position:relative;text-align:left;width:100%}.TopicChaptersMenu-module--toggleButton--2MGXA:focus{outline:.25rem solid #0092a6;z-index:1}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded=false]+.stacked-nav{display:none}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded=true]{border-bottom:0;margin:0}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded=true]+.stacked-nav{display:block}@media(min-width:37.5em){.TopicChaptersMenu-module--toggleButton--2MGXA{display:none}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded]+.stacked-nav{display:block}}.TopicChaptersMenu-module--icon--27uSj{color:#005ea5;right:.5rem;position:absolute;top:50%;-webkit-transform:translateY(-50%);transform:translateY(-50%)}.ChapterContents-module--wrapper--3ONbu{position:relative}.ChapterContents-module--printBtn--Rk_Zs{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto;-webkit-appearance:none;-moz-appearance:none;appearance:none;background:none;border:0;bottom:100%;cursor:pointer;display:none;padding:0}.ChapterContents-module--printBtn--Rk_Zs:visited{color:#4c2c92}.ChapterContents-module--printBtn--Rk_Zs:hover{color:#2e8aca}.ChapterContents-module--printBtn--Rk_Zs:focus{outline:.25rem solid #0092a6;color:#005ea5}.ChapterContents-module--printBtn--Rk_Zs:active{color:#222}.ChapterContents-module--printBtn--Rk_Zs svg{font-size:1.25rem;line-height:1.75rem;color:#0e0e0e;margin-right:.5rem;vertical-align:text-bottom}.ChapterContents-module--printBtn--Rk_Zs:hover svg{color:#2e8aca}@media(min-width:37.5em){.ChapterContents-module--wrapper--3ONbu:after,.ChapterContents-module--wrapper--3ONbu:before{content:" ";display:table}.ChapterContents-module--wrapper--3ONbu:after{clear:both}.ChapterContents-module--menu--3Epka{float:left;margin-right:1rem;width:-webkit-calc(25% - .5rem);width:calc(25% - .5rem)}.ChapterContents-module--landing--3klSq,.ChapterContents-module--onThisPage--1333P{float:right;width:-webkit-calc(75% - .5rem);width:calc(75% - .5rem)}.ChapterContents-module--body--1XBoo{margin-left:calc(25% + .5rem);overflow:hidden;width:-webkit-calc(75% - .5rem);width:calc(75% - .5rem)}}@media(min-width:56.25em){.ChapterContents-module--printBtn--Rk_Zs{display:block;margin-bottom:3rem;position:absolute;right:0}.ChapterContents-module--menu--3Epka{margin-right:2rem;width:-webkit-calc(25% - 1rem);width:calc(25% - 1rem)}.ChapterContents-module--landing--3klSq{width:-webkit-calc(75% - 1rem);width:calc(75% - 1rem)}.ChapterContents-module--onThisPage--1333P{position:-webkit-sticky;position:sticky;top:0;width:-webkit-calc(16.66667% - 1rem);width:calc(16.66667% - 1rem)}.ChapterContents-module--body--1XBoo{margin-left:calc(25% + 1rem);width:-webkit-calc(58.33333% - 2rem);width:calc(58.33333% - 2rem)}}@media print{.ChapterContents-module--menu--3Epka,.ChapterContents-module--onThisPage--1333P,.ChapterContents-module--printBtn--Rk_Zs{display:none}.ChapterContents-module--body--1XBoo{width:100%}}.ChapterBody-module--wrapper--2HCfk>.visually-hidden:first-child+*>:first-child{margin-top:0}.ChapterBody-module--wrapper--2HCfk h2:focus,.ChapterBody-module--wrapper--2HCfk h3:focus,.ChapterBody-module--wrapper--2HCfk h4:focus,.ChapterBody-module--wrapper--2HCfk h5:focus,.ChapterBody-module--wrapper--2HCfk h6:focus{outline:0!important}.ChapterBody-module--basisWrapper--3JBM_{border:1px solid #adadad;margin-top:1rem;max-width:66ch}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--headerWrapper--qSIFw>:first-child{margin-top:0}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--body--2n0CK{padding:0 1rem 1rem}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--body--2n0CK>:last-child{margin-bottom:0}.ChapterBody-module--headerWrapper--qSIFw{padding:1rem;position:relative}.ChapterBody-module--toggleBtn--3g0p7{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto;-webkit-appearance:none;-moz-appearance:none;appearance:none;background:none;border:0;cursor:pointer;display:block;margin-top:-.5rem;padding:0}.ChapterBody-module--toggleBtn--3g0p7:visited{color:#4c2c92}.ChapterBody-module--toggleBtn--3g0p7:hover{color:#2e8aca}.ChapterBody-module--toggleBtn--3g0p7:focus{outline:.25rem solid #0092a6;color:#005ea5}.ChapterBody-module--toggleBtn--3g0p7:active{color:#222}.ChapterBody-module--toggleBtn--3g0p7:after{content:"";height:100%;left:0;position:absolute;top:0;width:100%}.ChapterBody-module--toggleBtn--3g0p7 svg{font-size:1.125rem;line-height:1.5rem;color:#0e0e0e;margin-right:.5rem;vertical-align:text-bottom}.ChapterBody-module--toggleBtn--3g0p7:hover svg{color:#2e8aca}.ChapterBody-module--body--2n0CK[aria-hidden=true]{display:none}@media print{.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--headerWrapper--qSIFw>:first-child{margin-bottom:0}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--body--2n0CK[aria-hidden=true]{display:block}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--toggleBtn--3g0p7{display:none}}.ChapterOnThisPage-module--wrapper--2zc7n{margin-bottom:2rem}.ChapterOnThisPage-module--heading--2SdDN{margin-top:0}.ChapterOnThisPage-module--rootList--2II70{list-style:disc}.ChapterOnThisPage-module--subList--Pwxy9{list-style:circle}.ChapterOnThisPage-module--basisForRecs--1xLSs{display:none}@media(min-width:56.25em){.ChapterOnThisPage-module--heading--2SdDN{font-size:1.25rem;line-height:1.75rem;margin-bottom:1rem;margin-top:0}@supports((position:-webkit-sticky) or (position:sticky)){.ChapterOnThisPage-module--rootList--2II70 a[aria-current=location]{font-weight:700}.ChapterOnThisPage-module--rootList--2II70 a:focus+.ChapterOnThisPage-module--subList--Pwxy9{clip:auto;height:auto;overflow:visible;position:static!important;width:auto}.ChapterOnThisPage-module--subList--Pwxy9{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.ChapterOnThisPage-module--subList--Pwxy9:focus-within{clip:auto;height:auto;overflow:visible;position:static!important;width:auto}.ChapterOnThisPage-module--expandedSubList--1m1WN{clip:auto;height:auto;overflow:visible;position:static!important;width:auto}.ChapterOnThisPage-module--basisForRecs--1xLSs{display:list-item}}}</style><link rel="sitemap" type="application/xml" href="../../../../sitemap.xml"/><title data-react-helmet="true">Scenario: Stable COPD | Management | Chronic obstructive pulmonary disease | CKS | NICE</title><link data-react-helmet="true" rel="search" type="application/opensearchdescription+xml" href="../../../../opensearch.xml" title="CKS"/><link data-react-helmet="true" rel="icon" href="../../../../favicon.ico"/><link data-react-helmet="true" rel="canonical" href="index.html"/><meta data-react-helmet="true" name="description" content="Covers the management of people with persistent symptoms of COPD who are not experiencing an acute exacerbation."/><meta data-react-helmet="true" property="og:description" content="Covers the management of people with persistent symptoms of COPD who are not experiencing an acute exacerbation."/><meta data-react-helmet="true" property="og:url" content="https://cks.nice.org.uk/topics/chronic-obstructive-pulmonary-disease/management/stable-copd/"/><meta data-react-helmet="true" property="og:locale" content="en_GB"/><meta data-react-helmet="true" property="og:type" content="website"/><meta data-react-helmet="true" property="og:title" content="Scenario: Stable COPD | Management | Chronic obstructive pulmonary disease | CKS | NICE"/><meta data-react-helmet="true" property="og:image" content="https://cks.nice.org.uk/open-graph-image.png"/><meta data-react-helmet="true" property="og:image:width" content="1200"/><meta data-react-helmet="true" property="og:image:height" content="630"/><meta data-react-helmet="true" name="twitter:card" content="summary"/><meta data-react-helmet="true" name="twitter:image" content="https://cks.nice.org.uk/twitter-summary-image.png"/><meta data-react-helmet="true" name="twitter:image:alt" content="NICE and CKS logos"/><meta data-react-helmet="true" name="twitter:site" content="@NICEcomms"/><meta data-react-helmet="true" name="twitter:creator" content="@NICEcomms"/><meta data-react-helmet="true" name="theme-color" content="#004650"/><script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl+'';f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer', 'GTM-54QC4NL');</script><link rel="manifest" href="../../../../manifest.webmanifest" crossorigin="anonymous"/><meta name="theme-color" content="#004650"/><link rel="apple-touch-icon" sizes="48x48" href="../../../../icons/icon-48x48.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="72x72" href="../../../../icons/icon-72x72.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="96x96" href="../../../../icons/icon-96x96.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="144x144" href="../../../../icons/icon-144x144.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="192x192" href="../../../../icons/icon-192x192.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="256x256" href="../../../../icons/icon-256x256.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="384x384" href="../../../../icons/icon-384x384.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="512x512" href="../../../../icons/icon-512x512.png@v=28734348209eeeae5c03a37867f1beb1"/><link as="script" rel="preload" href="../../../../webpack-runtime-28c424ef71f39faedaf0.js"/><link as="script" rel="preload" href="../../../../framework-34da02e39e1f104d9937.js"/><link as="script" rel="preload" href="../../../../app-53a71c38b210970893c4.js"/><link as="script" rel="preload" href="../../../../b95b9d9ffa67e6928854e772968693a58a7317d7-a9e1e5c953d4eee49b87.js"/><link as="script" rel="preload" href="../../../../0ad1f03a47300760909b2ab244b34289611800a7-fa70b32ffeeba2673019.js"/><link as="script" rel="preload" href="../../../../component---src-templates-chapter-level-2-chapter-level-2-tsx-3330d13663fb7ba90e1c.js"/><link as="fetch" rel="preload" href="../../../../page-data/topics/chronic-obstructive-pulmonary-disease/management/stable-copd/page-data.json" crossorigin="anonymous"/><link as="fetch" rel="preload" href="../../../../page-data/sq/d/3666801979.json" crossorigin="anonymous"/><link as="fetch" rel="preload" href="../../../../page-data/app-data.json" crossorigin="anonymous"/><script src="https://cdn.nice.org.uk/cookie-banner/cookie-banner.min.js" type="text/javascript" async=""></script></head><body><noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54QC4NL" height="0" width="0" style="display: none; visibility: hidden" aria-hidden="true"></iframe></noscript><div id="___gatsby"><div style="outline:none" tabindex="-1" id="gatsby-focus-wrapper"><div><div class="Header-module--header--3os44"><header aria-label="Site header"><ul class="SkipLinks-module--list--1WwLa" aria-label="Accessibility links"><li><a href="index.html#content-start" class="SkipLinks-module--link--hkZw8">Skip to content</a></li><li><a href="https://www.nice.org.uk/accessibility" class="SkipLinks-module--link--hkZw8">Accessibility help</a></li></ul><div class="Header-module--container--1mfIr"><a href="https://www.nice.org.uk/" aria-label="Home" class="Header-module--home--1TCPb"><svg viewBox="0 0 4616 512" fill="none" class="Header-module--icon--4LSt5" aria-hidden="true" focusable="false"><path d="M1626 44v175h-22L1497 71v148h-19V44h22l107 147V44h19zm130 154a52 52 0 01-47 23c-18 0-34-7-45-20a70 70 0 01-18-48c0-19 6-35 18-48 11-14 27-20 47-20 19 0 34 8 45 23V87h20v132h-20v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35s-4-26-12-35c-8-10-19-15-33-15s-25 5-34 15c-8 9-12 21-12 35s4 26 12 35c9 10 20 15 34 15zm109 16V104h-27V87h27V40h19v47h30v17h-30v115h-19zm88-180v26h-21V39h21zm-20 48h20v132h-20V87zm107-2c20 0 35 6 48 20 11 12 17 28 17 48 0 19-6 36-17 48a61 61 0 01-48 20c-19 0-35-7-47-20a69 69 0 01-17-48c0-20 5-36 17-48 12-14 28-20 47-20zm0 118c14 0 25-5 34-15 7-9 11-21 11-35s-4-26-11-35c-9-10-20-15-34-15s-25 5-33 15c-8 9-12 21-12 35s4 26 12 35c8 10 19 15 33 15zm107-116v21c5-7 11-12 18-17 6-4 14-6 23-6 8 0 16 1 22 4 6 2 12 6 17 11 10 10 16 24 16 42v77h-20v-76c0-13-3-22-10-29-7-8-16-11-26-11a38 38 0 00-40 40v76h-19V87h19zm222 111a52 52 0 01-46 23c-19 0-34-7-46-20a71 71 0 01-17-48c0-19 5-35 17-48 12-14 27-20 47-20 19 0 35 8 45 23V87h20v132h-20v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35s-4-26-12-35c-8-10-19-15-33-15s-25 5-34 15c-8 9-12 21-12 35s4 26 12 35c9 10 20 15 34 15zm114 16h-19V34h19v185zm108 0h-19V44h19v175zm55-132v21c5-7 10-12 17-17 7-4 15-6 23-6 9 0 17 1 23 4 6 2 12 6 16 11 11 10 16 24 16 42v77h-19v-76c0-13-4-22-10-29-7-8-16-11-27-11a38 38 0 00-39 40v76h-19V87h19zm202 35c-2-13-13-20-33-20s-30 6-30 19c0 5 2 9 6 12 5 2 10 5 16 6l21 5 21 7c7 2 12 6 16 11 5 5 7 11 7 19 0 13-5 23-15 30-9 7-22 10-38 10-18 0-32-4-42-13-9-8-14-18-15-31h20c2 13 8 21 21 25l13 2 13-1 11-3c8-3 12-9 12-17 0-5-2-9-6-12s-10-6-16-7l-21-5-21-7c-7-2-12-6-16-10-4-5-6-11-6-19 0-12 4-22 12-28 9-7 22-10 39-10 15 0 28 4 37 11 8 7 12 16 14 26h-20zm60 97V104h-26V87h26V40h20v47h30v17h-30v115h-20zm89-180v26h-21V39h21zm-21 48h20v132h-20V87zm65 132V104h-26V87h26V40h20v47h30v17h-30v115h-20zm162 0v-21c-4 7-10 12-17 16-7 5-14 7-23 7s-16-1-22-4c-7-2-12-6-17-11a57 57 0 01-16-42V87h20v76c0 12 3 22 10 29 6 7 15 11 26 11a39 39 0 0039-40V87h20v132h-20zm65 0V104h-26V87h26V40h20v47h30v17h-30v115h-20zm124-16c17 0 30-7 37-22h22c-5 12-12 22-22 29-9 7-22 11-38 11-19 0-35-7-47-20a68 68 0 01-18-48c0-20 5-36 17-48 12-14 28-20 47-20 20 0 35 6 48 20 11 12 17 28 17 48v8h-109c1 12 6 22 14 30s19 12 32 12zm-2-100c-12 0-22 4-30 11s-12 17-14 28h88c-1-11-6-21-14-28s-18-11-30-11zm195-52c-9 0-16 2-21 6-4 4-7 11-7 20v10h30v17h-30v115h-19V104h-23V87h23V75c0-14 4-25 12-32 9-7 21-11 36-11h1v19h-2zm75 34c19 0 35 6 47 20 12 12 18 28 18 48 0 19-6 36-18 48a61 61 0 01-47 20c-19 0-35-7-47-20a69 69 0 01-18-48c0-20 6-36 18-48 12-14 28-20 47-20zm0 118c14 0 25-5 33-15 8-9 12-21 12-35s-4-26-12-35c-8-10-19-15-33-15s-25 5-33 15c-8 9-12 21-12 35s4 26 12 35c8 10 19 15 33 15zm156-118v20h-2c-14 0-25 5-34 17-9 11-13 24-13 39v58h-19V87h19v32c4-13 13-23 27-30 6-3 13-4 21-4h1zM1617 293v175h-19v-78h-101v78h-19V293h19v78h101v-78h19zm91 159c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-23 11-38 11-20 0-36-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 12-13 28-19 48-19 19 0 35 6 47 19 11 13 17 29 17 49v8h-109c1 12 6 22 14 30 9 8 19 12 32 12zm-1-100c-12 0-22 3-31 11-7 7-12 17-14 28h89c-2-11-7-21-14-28-8-8-18-11-30-11zm187 95a52 52 0 01-47 23c-18 0-34-7-45-20a70 70 0 01-18-48c0-19 6-36 18-49 11-13 27-19 47-19 19 0 34 7 45 23v-21h20v132h-20v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm114 16h-19V283h19v185zm46 0V353h-27v-17h27v-48h19v48h30v17h-30v115h-19zm87-185v73l17-16c7-4 15-6 24-6 8 0 16 1 22 3a58 58 0 0133 54v77h-20v-77c0-12-3-21-10-29-7-7-16-10-26-10a39 39 0 00-40 40v76h-19V283h19zm280 164a52 52 0 01-47 23c-19 0-34-7-46-20a70 70 0 01-17-48c0-19 6-36 17-49 12-13 28-19 47-19 20 0 35 7 46 23v-21h19v132h-19v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm109-116v20c5-6 10-11 17-16 7-4 15-6 23-6 9 0 17 1 23 3 6 3 11 6 16 11 11 11 16 25 16 43v77h-19v-77c0-12-4-21-10-29-7-7-16-10-27-10a39 39 0 00-39 40v76h-19V336h19zm222 111a52 52 0 01-47 23c-19 0-34-7-46-20a71 71 0 01-17-48c0-19 6-36 17-49 12-13 28-19 47-19 20 0 35 7 46 23v-74h19v185h-19v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm233-1a56 56 0 0053-36h21c-6 17-15 30-28 39a82 82 0 01-50 16c-25 0-46-9-61-26a92 92 0 01-22-64c0-25 7-46 22-63 15-18 36-26 61-26a78 78 0 0178 54h-21c-4-11-11-19-20-25-10-7-20-10-33-10-12 0-22 2-30 5-9 4-15 9-21 15a73 73 0 00-17 50c0 21 6 37 17 50 12 14 29 21 51 21zm198-4a52 52 0 01-47 23c-19 0-34-7-46-20a70 70 0 01-17-48c0-19 6-36 17-49 12-13 28-19 48-19 19 0 34 7 45 23v-21h19v132h-19v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm163-118v19h-2c-14 0-26 6-34 18-9 10-13 23-13 39v58h-19V336h19v32c4-14 13-24 27-30 6-3 13-4 21-4h1zm73 118c18 0 31-8 38-22h21c-4 12-11 21-21 29-10 7-22 11-38 11-19 0-35-7-48-20a68 68 0 01-18-48c0-20 6-36 18-49s27-19 47-19c19 0 35 6 47 19s17 29 17 49v8h-109c2 12 7 22 15 30s19 12 31 12zm-1-100c-12 0-22 3-30 11-8 7-13 17-14 28h88c-2-11-6-21-14-28-8-8-18-11-30-11zm162-40v59h96v19h-96v59h108v19h-127V293h127v19h-108zm189 88l51 68h-25l-37-54-37 54h-25l51-68-48-64h25l34 50 33-50h25l-47 64zm120 52c9 0 16-3 23-7 6-5 11-11 14-19h21c-4 13-12 24-22 32-11 8-24 12-40 12-19 0-34-7-46-20a69 69 0 01-18-48c0-20 6-36 18-49s27-19 46-19a60 60 0 0161 44h-20c-3-8-8-15-14-19-7-5-14-7-23-7-8 0-15 1-21 4-6 2-10 6-14 10-9 10-13 22-13 36s4 26 13 35c8 10 20 15 35 15zm137 0c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-22 11-38 11-20 0-35-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 13-13 28-19 48-19 19 0 35 6 47 19s17 29 17 49v8h-109c2 12 6 22 15 30 8 8 19 12 31 12zm-1-100c-12 0-22 3-30 11-8 7-13 17-14 28h88c-2-11-6-21-14-28-8-8-18-11-30-11zm105 116h-19V283h19v185zm51 0h-20V283h20v185zm89-16c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-23 11-38 11-20 0-36-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 12-13 28-19 48-19 19 0 35 6 47 19 11 13 17 29 17 49v8h-109c2 12 6 22 14 30 9 8 19 12 32 12zm-1-100c-12 0-22 3-31 11-7 7-12 17-14 28h89c-2-11-7-21-14-28-8-8-18-11-30-11zm105-16v20c5-6 10-11 17-16 7-4 15-6 23-6 9 0 17 1 23 3 6 3 12 6 16 11 11 11 16 25 16 43v77h-19v-77c0-12-4-21-10-29-7-7-16-10-27-10s-20 3-28 11c-7 7-11 17-11 29v76h-19V336h19zm185 116a40 40 0 0037-26h21c-4 13-12 24-22 32-11 8-25 12-40 12-19 0-34-7-46-20a69 69 0 01-18-48c0-20 6-36 18-49s27-19 46-19c15 0 29 4 40 12 10 8 18 18 22 31h-21c-3-7-8-14-15-18-6-5-13-7-22-7-8 0-15 1-21 4-6 2-11 6-15 10-8 10-12 22-12 36s4 26 12 35c9 10 21 15 36 15zm137 0c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-23 11-38 11-20 0-36-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 12-13 28-19 48-19 19 0 35 6 47 19s17 29 17 49v8h-109c2 12 6 22 15 30 8 8 18 12 31 12zm-1-100c-12 0-22 3-30 11-8 7-13 17-15 28h89c-2-11-6-21-14-28-8-8-18-11-30-11zM412 454c0 16-7 19-18 19h-53c-11 0-20-4-27-13L130 213h-2v242c0 13-6 18-18 18H52c-14 0-20-3-20-18V62c0-16 7-19 20-19h52c13 0 19 3 26 13l184 248h1V61c0-14 7-18 19-18h60c16 0 17 8 17 19v392h1zm197 4c0 7-5 14-14 14h-71c-9 0-14-7-14-14V56c0-8 5-15 14-15h71c9 0 14 7 14 14v403zm415-380l-18 52c-2 6-5 9-9 9l-8-2c-33-16-58-21-87-21-65 0-106 49-106 140 0 98 47 140 107 140 29 0 55-5 84-17l9-3c6 0 9 3 11 10l16 46 2 10c0 6-3 11-12 14-42 16-77 24-125 24-131 0-197-87-197-221S772 32 896 32c45 0 82 9 118 25 9 4 12 8 12 12l-2 9zm336-37c13 0 17 6 16 15l-6 50c-1 13-9 15-24 15h-149v93h140c14 0 19 7 19 17v45c0 12-7 18-18 18h-141v98h161c11 0 18 5 18 17v46c0 11-6 17-17 17h-240c-14 0-21-4-21-19V59c0-11 6-18 16-18h246z" fill="currentColor"></path></svg></a><div class="Header-module--wrapper--2e13D"><div class="Header-module--search--2nfnz"><form id="global-nav-search-form" role="search" action="https://cks.nice.org.uk/search" class="Search-module--search--2wNll"><label class="Search-module--label--1rrog" for="autocomplete">Search CKS</label><div class="Autocomplete-module--ac--2PqiF"><div class="autocomplete__wrapper"><input type="search" id="autocomplete" name="q" class="autocomplete__input autocomplete__input--default" placeholder="Search CKS" data-hj-allow="" maxLength="512" value=""/></div></div><button class="Search-module--button--2FbnI" type="submit" aria-label="Perform search"><svg width="1em" height="1em" viewBox="0 0 512 512" fill="none" class="Search-module--icon--2JB42" aria-hidden="true" focusable="false"><path d="M83.784 476.472L197.112 363.16c30.144 20.32 65.056 30.528 100.032 30.528 45.904 0 91.776-17.488 126.8-52.528 70.064-70.064 70.064-183.584 0-253.616C388.936 52.504 343.048 35 297.144 35c-45.904 0-91.808 17.504-126.848 52.528-61.696 61.696-68.976 157.12-21.968 226.864L35 427.752l48.784 48.72zm213.36-137.952c-33.168 0-64.352-12.896-87.792-36.368-48.416-48.448-48.416-127.2 0-175.616 23.44-23.44 54.64-36.352 87.792-36.352s64.336 12.912 87.776 36.368c23.44 23.456 36.384 54.64 36.384 87.792s-12.928 64.352-36.384 87.792c-23.456 23.472-54.624 36.368-87.776 36.368v.016z" fill="currentColor"></path></svg></button></form></div><button class="Header-module--mobileMenuBtn--1LgyL" id="header-menu-button" type="button" aria-controls="header-menu" aria-expanded="false" aria-haspopup="menu" aria-label="Expand site menu">Menu</button></div></div><div id="header-menu" class="Nav-module--wrapper--2_xng Nav-module--wrapperWithSubLinks--3PUfX"><nav class="Nav-module--nav--2aQpa" aria-label="primary navigation"><div class="Nav-module--menuWrapper--2fp8S"><ul class="Nav-module--menuList--264L-" aria-labelledby="header-menu-button"><li><a href="https://pathways.nice.org.uk/" class="Nav-module--link--3JzDA">NICE Pathways</a></li><li><a href="https://www.nice.org.uk/guidance" class="Nav-module--link--3JzDA">NICE guidance</a></li><li><a href="https://www.nice.org.uk/standards-and-indicators" class="Nav-module--link--3JzDA">Standards and indicators</a></li><li><a href="https://www.evidence.nhs.uk/" class="Nav-module--link--3JzDA">Evidence search</a></li><li><a href="https://bnf.nice.org.uk/" class="Nav-module--link--3JzDA"><abbr title="British National Formulary">BNF<!-- --> <span class="Nav-module--visuallyHidden--ORHqX">British National Formulary</span></abbr><span aria-hidden="true" class="Nav-module--tooltip--1Uj-W">British National Formulary</span></a></li><li><a href="https://bnfc.nice.org.uk/" class="Nav-module--link--3JzDA"><abbr title="British National Formulary for Children">BNFC<!-- --> <span class="Nav-module--visuallyHidden--ORHqX">British National Formulary for Children</span></abbr><span aria-hidden="true" class="Nav-module--tooltip--1Uj-W">British National Formulary for Children</span></a></li><li><a href="../../../../index.html" aria-current="true" class="Nav-module--link--3JzDA"><abbr title="Clinical Knowledge Summaries">CKS<!-- --> <span class="Nav-module--visuallyHidden--ORHqX">Clinical Knowledge Summaries</span></abbr><span aria-hidden="true" class="Nav-module--tooltip--1Uj-W">Clinical Knowledge Summaries</span></a><div class="SubNav-module--wrapper--yAXWY"><ul class="SubNav-module--list--1K9bK" aria-label="CKS links"><li class="SubNav-module--imageLink--3xwIS"><a href="../../../../index.html" class="SubNav-module--link--39i23" aria-label="CKS - Home"><img src="data:image/svg+xml;base64,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" class="SubNav-module--image--uq-a2" alt=""/></a></li><li><a href="../../../index.html" class="SubNav-module--link--39i23" aria-label="Health topics A to Z">Health topics A to Z</a></li><li><a href="../../../../specialities/index.html" class="SubNav-module--link--39i23" aria-label="Specialities">Specialities</a></li><li><a href="../../../../whats-new/index.html" class="SubNav-module--link--39i23" aria-label="What&#x27;s new">What&#x27;s new</a></li><li><a href="../../../../about/index.html" class="SubNav-module--link--39i23" aria-label="About CKS">About CKS</a></li></ul></div></li><li><a href="https://www.nice.org.uk/about/what-we-do/evidence-services/journals-and-databases" class="Nav-module--link--3JzDA">Journals and databases</a></li></ul></div></nav></div></header><aside class="CoronaMessage-module--wrapper--zRiaV" aria-label="COVID-19 Notice"><div class="CoronaMessage-module--container--36Biz"><p>Read about<!-- --> <a href="https://www.nice.org.uk/covid-19">our approach to COVID-19</a></p></div></aside></div></div><main class="Layout-module--main--1OIFf" id="content-start"><div class="container"><nav aria-label="Breadcrumbs" role="navigation"><ol class="breadcrumbs"><li class="breadcrumbs__crumb"><a href="https://www.nice.org.uk/">NICE</a></li><li class="breadcrumbs__crumb"><a href="../../../../index.html">CKS</a></li><li class="breadcrumbs__crumb"><a href="../../../index.html">Health topics A to Z</a></li><li class="breadcrumbs__crumb"><a href="../../index.html">Chronic obstructive pulmonary disease</a></li><li class="breadcrumbs__crumb"><a href="../index.html">Management</a></li><li class="breadcrumbs__crumb"><span>Scenario: Stable COPD</span></li></ol></nav><script type="application/ld+json">{"@context":"http://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"item":{"@id":"https://www.nice.org.uk/","name":"NICE"}},{"@type":"ListItem","position":2,"item":{"@id":"/","name":"CKS"}},{"@type":"ListItem","position":3,"item":{"@id":"/topics/","name":"Health topics A to Z"}},{"@type":"ListItem","position":4,"item":{"@id":"/topics/chronic-obstructive-pulmonary-disease/","name":"Chronic obstructive pulmonary disease"}},{"@type":"ListItem","position":5,"item":{"@id":"/topics/chronic-obstructive-pulmonary-disease/management/","name":"Management"}},{"@type":"ListItem","position":6,"item":{"name":"Scenario: Stable COPD"}}]}</script><div class="page-header"><h1 class="page-header__heading"><span class="page-header__pre-heading">Chronic obstructive pulmonary disease: </span><span>Scenario: Stable chronic obstructive pulmonary disease</span></h1><p class="page-header__lead"><span>Last revised in October 2020</span></p></div><p class="visually-hidden">Covers the management of people with persistent symptoms of COPD who are not experiencing an acute exacerbation.</p><div class="ChapterContents-module--wrapper--3ONbu"><div class="ChapterContents-module--menu--3Epka"><nav class="stacked-nav" aria-label="Chronic obstructive pulmonary disease chapters"><ul class="stacked-nav__list"><li class="stacked-nav__list-item" data-tracking="Summary"><a aria-current="false" href="../../index.html"><span class="stacked-nav__content-wrapper">Summary</span></a></li><li class="stacked-nav__list-item" data-tracking="Have I got the right topic?"><a aria-current="false" href="../../have-i-got-the-right-topic/index.html"><span class="stacked-nav__content-wrapper">Have I got the right topic?</span></a></li><li class="stacked-nav__list-item" data-tracking="How up-to-date is this topic?"><a aria-current="false" href="../../how-up-to-date-is-this-topic/index.html"><span class="stacked-nav__content-wrapper">How up-to-date is this topic?</span></a></li><li class="stacked-nav__list-item" data-tracking="Goals and outcome measures"><a aria-current="false" href="../../goals-outcome-measures/index.html"><span class="stacked-nav__content-wrapper">Goals and outcome measures</span></a></li><li class="stacked-nav__list-item" data-tracking="Background information"><a aria-current="false" href="../../background-information/index.html"><span class="stacked-nav__content-wrapper">Background information</span></a></li><li class="stacked-nav__list-item" data-tracking="Diagnosis"><a aria-current="false" href="../../diagnosis/index.html"><span class="stacked-nav__content-wrapper">Diagnosis</span></a></li><li class="stacked-nav__list-item" data-tracking="Management"><a aria-current="false" href="../index.html"><span class="stacked-nav__content-wrapper">Management</span></a><ul class="stacked-nav__nested"><li class="stacked-nav__list-item" data-tracking="Management | Scenario: Stable COPD"><a aria-current="true" class="" href="index.html"><span class="stacked-nav__content-wrapper">Scenario: Stable COPD</span></a></li><li class="stacked-nav__list-item" data-tracking="Management | Scenario: Acute exacerbation"><a aria-current="false" href="../acute-exacerbation/index.html"><span class="stacked-nav__content-wrapper">Scenario: Acute exacerbation</span></a></li><li class="stacked-nav__list-item" data-tracking="Management | Scenario: End-stage COPD"><a aria-current="false" href="../end-stage-copd/index.html"><span class="stacked-nav__content-wrapper">Scenario: End-stage COPD</span></a></li><li class="stacked-nav__list-item" data-tracking="Management | Scenario: COVID-19"><a aria-current="false" href="../covid-19/index.html"><span class="stacked-nav__content-wrapper">Scenario: COVID-19</span></a></li></ul></li><li class="stacked-nav__list-item" data-tracking="Prescribing information"><a aria-current="false" href="../../prescribing-information/index.html"><span class="stacked-nav__content-wrapper">Prescribing information</span></a></li><li class="stacked-nav__list-item" data-tracking="Supporting evidence"><a aria-current="false" href="../../supporting-evidence/index.html"><span class="stacked-nav__content-wrapper">Supporting evidence</span></a></li><li class="stacked-nav__list-item" data-tracking="How this topic was developed"><a aria-current="false" href="../../how-this-topic-was-developed/index.html"><span class="stacked-nav__content-wrapper">How this topic was developed</span></a></li><li class="stacked-nav__list-item" data-tracking="References"><a aria-current="false" href="../../references/index.html"><span class="stacked-nav__content-wrapper">References</span></a></li></ul></nav></div><div class="ChapterContents-module--onThisPage--1333P"><nav class="ChapterOnThisPage-module--wrapper--2zc7n" aria-labelledby="on-this-page"><h2 class="ChapterOnThisPage-module--heading--2SdDN" id="on-this-page">On this page</h2><ol class="ChapterOnThisPage-module--rootList--2II70" aria-label="Jump links to section on this page"><li><a href="index.html#referral">Referral</a><ol aria-label="Sections within Referral" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class=""><a href="index.html#referral-to-a-respiratory-specialist">Referral to a respiratory specialist</a></li><li class=""><a href="index.html#referral-for-pulmonary-rehabilitation">Referral for pulmonary rehabilitation</a></li><li class=""><a href="index.html#referral-for-oxygen-therapy-assessment">Referral for oxygen therapy assessment</a></li><li class=""><a href="index.html#referral-to-multidisciplinary-team">Referral to multidisciplinary team</a></li></ol></li><li><a href="index.html#treatment">Treatment</a><ol aria-label="Sections within Treatment" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class=""><a href="index.html#non-pharmacological-treatments-inhaled-treatments">Non-pharmacological treatments and inhaled treatments</a></li><li class=""><a href="index.html#delivery-systems">Delivery systems</a></li><li class=""><a href="index.html#add-on-treatments">Add-on treatments</a></li></ol></li><li><a href="index.html#self-management-plan">Self-management plan</a><ol aria-label="Sections within Self-management plan" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-429">Basis for recommendation</a></li></ol></li><li><a href="index.html#advice">Advice</a><ol aria-label="Sections within Advice" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class=""><a href="index.html#advice-about-flying">Advice about flying</a></li><li class=""><a href="index.html#advice-about-driving">Advice about driving</a></li></ol></li><li><a href="index.html#follow-up">Follow up</a><ol aria-label="Sections within Follow up" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-5fd">Basis for recommendation</a></li></ol></li></ol></nav></div><div class="ChapterContents-module--body--1XBoo"><section aria-labelledby="stable-copd" class="ChapterBody-module--wrapper--2HCfk "><h2 id="stable-copd" class="visually-hidden">Scenario: Stable chronic obstructive pulmonary disease</h2><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item cba50cec-5367-47d2-b385-35ff6edce3d4 --><!-- begin field 3cf0d667-166d-4fbe-a913-acd900adb503 --><p>From age 16 years onwards.</p><!-- end field 3cf0d667-166d-4fbe-a913-acd900adb503 --><!-- end item cba50cec-5367-47d2-b385-35ff6edce3d4 --></div><section aria-labelledby="referral" class="ChapterBody-module--wrapper--2HCfk "><h3 id="referral">When should I refer a person with COPD?</h3><section aria-labelledby="referral-to-a-respiratory-specialist" class="ChapterBody-module--wrapper--2HCfk "><h4 id="referral-to-a-respiratory-specialist">When should I refer a person with COPD to a respiratory specialist?</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 30b0d560-77d9-453d-a955-3fab3266a292 --><!-- begin field 70a6f6c4-4a2a-4264-935f-0fce45e14bbe --><ul><li><strong>Refer the person to a respiratory specialist (with urgency depending on the clinical situation), if:</strong><ul><li>Lung cancer is suspected (for example they have haemoptysis or suspicious features on chest X-ray).<ul><li>For more information, see the CKS topic on <a class="topic-reference external-reference" href="../../../lung-pleural-cancers-recognition-referral/index.html">Lung and pleural cancers - recognition and referral</a>.</li></ul></li><li>There is diagnostic uncertainty, for example:<ul><li>Difficulty distinguishing COPD from asthma or other conditions such as bronchiectasis or pulmonary fibrosis.</li><li>Symptoms are disproportionate to findings on spirometry.</li></ul></li><li>COPD is very severe or rapidly worsening.<ul><li>For example, forced expiratory volume in 1 second (FEV1) is less than 30% predicted or rapidly declining.</li></ul></li><li><a class="topic-reference internal-reference" href="../../diagnosis/diagnosis-copd/index.html#cor-pulmonale">Cor pulmonale</a> is suspected.</li><li>The person is less than 40 years of age and/or there is a family history of alpha-1-antitrypsin deficiency.<ul><li>If alpha-1-antitrypsin deficiency is confirmed, screening is indicated for the person's family.</li></ul></li><li>They have frequent infections  to assess preventable factors and exclude bronchiectasis.<ul><li>For more information, see the CKS topic on <a class="topic-reference external-reference" href="../../../bronchiectasis/index.html">Bronchiectasis</a>.</li></ul></li></ul></li><li><strong>Referral to a respiratory specialist may also be required to assess the need for:</strong><ul><li>Oxygen therapy.</li><li>Long-term non-invasive ventilation.</li><li>Nebulizer therapy or long-term oral corticosteroids.</li><li>Lung surgery (for example, for a person with bullous lung disease who is still symptomatic on maximal treatment).</li></ul></li></ul><!-- end field 70a6f6c4-4a2a-4264-935f-0fce45e14bbe --><!-- end item 30b0d560-77d9-453d-a955-3fab3266a292 --></div><section aria-labelledby="basis-for-recommendation-aa2" class="ChapterBody-module--wrapper--2HCfk "><h5 id="basis-for-recommendation-aa2">Basis for recommendation</h5><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item aa25c1ed-f754-419e-bcfb-bf1517824784 --><!-- begin field 22ec5a51-a10f-4e52-8d00-189d75855f39 --><p>The recommendations on when to refer a person with stable chronic obstructive pulmonary disease (COPD) are based on the clinical guidelines <em>Diagnosis and initial treatment of asthma, COPD and asthma-COPD overlap</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">GINA and GOLD, 2017</a>], <em>COPD-X: concise guide for primary care</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Lung Foundation Australia, 2017</a>], <em>Global initiative for chronic obstructive lung disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2019 report</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">GOLD, 2019</a>], and<em>Chronic obstructive pulmonary disease in over 16s: diagnosis and management</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2019a</a>].</p><ul><li>The GINA and GOLD guideline on asthma-COPD overlap recommends referral for specialist input as the outcome is often worse for asthma-COPD overlap then for either condition alone (in terms of frequency of exacerbations, quality of life, decline in lung function and mortality) [<a class="bibliography-reference internal-reference" href="../../references/index.html">GINA and GOLD, 2017</a>].</li><li>The GOLD guideline recommends long-term non-invasive ventilation in people with severe chronic hypercapnia and history of hospitalization for acute respiratory failure as this can decrease mortality and prevent re-hospitalization [<a class="bibliography-reference internal-reference" href="../../references/index.html">GOLD, 2019</a>].</li></ul><!-- end field 22ec5a51-a10f-4e52-8d00-189d75855f39 --><!-- end item aa25c1ed-f754-419e-bcfb-bf1517824784 --></div></section></section><section aria-labelledby="referral-for-pulmonary-rehabilitation" class="ChapterBody-module--wrapper--2HCfk "><h4 id="referral-for-pulmonary-rehabilitation">When should I refer a person with COPD for pulmonary rehabilitation?</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 062ed6ff-5718-49bf-88ec-8b6e9c162fc2 --><!-- begin field 64cd264a-6afe-4304-8d66-44d007c0f75c --><p>Pulmonary rehabilitation is individually tailored, multidisciplinary care program for people with COPD which aims to optimize physical and psychological condition through exercise training, education, and nutritional, psychological, and behavioural interventions.</p><ul><li><strong>Refer the person for pulmonary rehabilitation</strong> if they are functionally disabled by chronic obstructive pulmonary disease (COPD) (usually <a class="topic-reference internal-reference" href="../../diagnosis/diagnosis-copd/index.html#medical-research-council-dyspnoea-scale">Medical Research Council (MRC) dyspnoea scale</a> grade 3 or above), or have had a recent hospitalization for an acute exacerbation.<ul><li>Refer directly for pulmonary rehabilitation if possible, depending on local referral pathways.</li><li>Advise the person that commitment to pulmonary rehabilitation can improve quality of life, increase exercise capacity and reduce breathlessness.</li></ul></li><li><strong>Do not refer the person for pulmonary rehabilitation if they:</strong><ul><li>Are unable to walk</li><li>Have unstable angina, or have had a recent myocardial infarction.</li></ul></li></ul><!-- end field 64cd264a-6afe-4304-8d66-44d007c0f75c --><!-- end item 062ed6ff-5718-49bf-88ec-8b6e9c162fc2 --></div><section aria-labelledby="basis-for-recommendation-fdc" class="ChapterBody-module--wrapper--2HCfk "><h5 id="basis-for-recommendation-fdc">Basis for recommendation</h5><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item fdc67e6e-9bcc-4744-8117-acd2ac6e6431 --><!-- begin field 82f7167b-beef-4953-ad80-4d60bb320e7b --><p>The recommendations on referral for pulmonary rehabilitation are based on the clinical guidelines <em>Diagnosis and initial treatment of asthma, COPD and asthma-COPD overlap</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">GINA and GOLD, 2017</a>], <em>COPD-X: concise guide for primary care</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Lung Foundation Australia, 2017</a>], <em>Chronic obstructive pulmonary disease (COPD): best practice guide</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Scottish Government, 2017</a>], <em>Global initiative for chronic obstructive lung disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2019 report</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">GOLD, 2019</a>], and<em>Chronic obstructive pulmonary disease in over 16s: diagnosis and management</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2019a</a>].</p><ul><li>Guidance from NICE and GOLDrecommendpulmonary rehabilitation as it is an effective therapeutic strategy for improving breathlessness, health-related quality of life and exercise tolerance [<a class="bibliography-reference internal-reference" href="../../references/index.html">GOLD, 2019</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2019a</a>].</li><li>NICE recommends referral to pulmonary rehabilitation for all people with stable COPD and exercise limitation due to breathlessness and those admitted to hospital for an acute exacerbation of COPD (to start a pulmonary rehabilitation programme within 4 weeks of discharge) [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2019a</a>].</li></ul><!-- end field 82f7167b-beef-4953-ad80-4d60bb320e7b --><!-- end item fdc67e6e-9bcc-4744-8117-acd2ac6e6431 --></div></section></section><section aria-labelledby="referral-for-oxygen-therapy-assessment" class="ChapterBody-module--wrapper--2HCfk "><h4 id="referral-for-oxygen-therapy-assessment">When should I refer a person with COPD for assessment for oxygen therapy?</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 57f8f3db-1b46-48b9-91b9-44977ae75a70 --><!-- begin field d128a6e1-9def-41e2-b909-274daf5752b4 --><ul><li><strong>Do not start oxygen therapy without a specialist assessment.</strong><ul><li>Oxygen is a treatment for hypoxaemia (not breathlessness).<ul><li>Long-term oxygen therapy (LTOT) can improve survival in people with stable COPD and chronic hypoxia.</li><li>Inappropriate oxygen therapy in people with COPD may cause respiratory depression.</li></ul></li></ul></li><li><strong>Refer the person for LTOT assessment if they have:</strong><ul><li>Oxygen saturations of 92% or less breathing air.</li><li>Very severe (forced expiratory volume in 1 second [FEV1] less than 30% predicted) or severe (FEV1 3049% predicted) airflow obstruction.</li><li>Cyanosis.</li><li>Polycythaemia.</li><li>Peripheral oedema.</li><li>Raised jugular venous pressure.</li></ul></li><li><strong>Refer for assessment for ambulatory oxygen therapy </strong>(portable oxygen) people on LTOT who are mobile outdoors.</li><li><strong>Do not offer short-burst oxygen therapy for breathlessness in people with COPD who have mild or no hypoxaemia at rest.</strong><ul><li>Palliative oxygen therapy may be considered by a specialist for people with intractable breathlessness which is non-responsive to other treatment.</li><li>For more information, see the section on <a class="topic-reference internal-reference" href="../end-stage-copd/index.html#how-should-i-manage-a-person-with-end-stage-copd">End of life care</a>.</li></ul></li><li><strong>Warn people using oxygen not to smoke because of the risk of fire or explosion.</strong><ul><li>For more information, see the <a href="https://www.brit-thoracic.org.uk/quality-improvement/guidelines/home-oxygen/" target="_blank" rel="noopener" data-hyperlink-id="0448c03a-9065-4116-be3d-ab1201001294">British Thoracic Society guideline for home oxygen use in adults</a>.</li></ul></li></ul><!-- end field d128a6e1-9def-41e2-b909-274daf5752b4 --><!-- end item 57f8f3db-1b46-48b9-91b9-44977ae75a70 --></div><section aria-labelledby="basis-for-recommendation-37c" class="ChapterBody-module--wrapper--2HCfk "><h5 id="basis-for-recommendation-37c">Basis for recommendation</h5><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 37c134f1-9743-4993-8be8-0e99daf6ea00 --><!-- begin field 033769be-8154-4ac0-bdb2-c37d17c3a9c9 --><p>The recommendations on referral for oxygen therapy are based on the clinical guidelines <em>British Thoracic Society (BTS) guidelines for home oxygen use in adults</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Hardinge, 2015</a>], <em>COPD-X: concise guide for primary care</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Lung Foundation Australia, 2017</a>], <em>Global initiative for chronic obstructive lung disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2019 report</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">GOLD, 2019</a>], and<em>Chronic obstructive pulmonary disease in over 16s: diagnosis and management</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2019a</a>], and expert opinion in a review article [<a class="bibliography-reference internal-reference" href="../../references/index.html">Suntharalingam, 2016</a>].</p><h6>Long-term oxygen therapy (LTOT)</h6><ul><li>Long-term oxygen therapy (LTOT) is defined as oxygen (delivered via an oxygen concentrator) which is used for at least 15 hours per day in people who are chronically hypoxic [<a class="bibliography-reference internal-reference" href="../../references/index.html">Hardinge, 2015</a>].</li><li>The NICE guideline recommendations are based on 4 randomised controlled trials looking at LTOT in people with COPD  outcomes included quality of life, mortality and adverse events. The overall quality of evidence was graded as very low to moderate. The guideline development committee agreed that LTOT can lead to a survival benefit in people with COPD with arterial oxygen pressure of less than 7.3kPa and less than 8 kPa when stable and either secondary polycythaemia, peripheral oedema or pulmonary hypertension.</li><li>The GOLD guideline states that LTOT improves survival in people with severe resting chronic hypoxaemia. Routine prescription of LTOT was not recommended for people with stable COPD and resting or exercise-induced moderate desaturation.</li></ul><h6>Ambulatory oxygen therapy (AOT)</h6><ul><li>AOT is defined as use of oxygen (delivered via a portable cylinder) during exercise and other exertion associated with activities of daily life [<a class="bibliography-reference internal-reference" href="../../references/index.html">Hardinge, 2015</a>].</li><li>NICE recommend that ambulatory oxygen is prescribed to people who are already on LTOT who want to continue oxygen therapy outside the home and that it should be considered in people with COPD who have exercise desaturation, demonstrated improvement in exercise capacity with oxygen, and motivation to use oxygen [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2019a</a>].</li><li>The NICE guideline committee did not identify evidence that showed that a clinically meaningful improvement in breathlessness for people with mild or no hypoxaemia with ambulatory oxygen [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2019a</a>].</li></ul><h6>Short-burst oxygen (SBOT) </h6><ul><li>SBOT is typically used intermittently at home for short periods (for example 15-20 minutes at a time) [<a class="bibliography-reference internal-reference" href="../../references/index.html">Suntharalingam, 2016</a>].</li><li>NICE and the BTS do not recommend short-burst oxygen therapy for people with mild or no hypoxaemia as evidence on meaningful benefit is lacking [<a class="bibliography-reference internal-reference" href="../../references/index.html">Hardinge, 2015</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2019a</a>].</li><li>The statement that palliative oxygen therapy may be considered by a specialist for people with intractable breathlessness non-responsive to other treatment is from the BTS guideline on home oxygen use in adults [<a class="bibliography-reference internal-reference" href="../../references/index.html">Hardinge, 2015</a>].</li></ul><!-- end field 033769be-8154-4ac0-bdb2-c37d17c3a9c9 --><!-- end item 37c134f1-9743-4993-8be8-0e99daf6ea00 --></div></section></section><section aria-labelledby="referral-to-multidisciplinary-team" class="ChapterBody-module--wrapper--2HCfk "><h4 id="referral-to-multidisciplinary-team">When should I refer a person with COPD to other professionals in the multidisciplinary team?</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item ada3ccc8-fd97-4425-b282-1da4d7b57d0b --><!-- begin field 84a7b6b4-2a43-4a80-9b9f-c644199b6ea6 --><ul><li><strong>Consider referral to a physiotherapist</strong> for a person with excessive sputum, to learn:<ul><li>How to use positive expiratory pressure devices.</li><li>Active cycle of breathing techniques.</li></ul></li><li><strong>Consider referral to social services and occupational therapy</strong> if:<ul><li>The person is experiencing difficulties with activities of daily living or functional disability.</li></ul></li><li><strong>Consider referral for dietetic advice</strong> if:<ul><li>Body Mass Index (BMI) is abnormal (high or low) or changing over time (3 kg or more in an older person).<ul><li>Other causes of unintentional weight loss (including malignancy) should be considered.</li><li>Nutrition should form part of all pulmonary rehabilitation programmes.</li><li>For information on obesity, see the CKS topic on <a class="topic-reference external-reference" href="../../../obesity/index.html">Obesity</a>.</li></ul></li></ul></li><li><strong>Consider referral to psychological services</strong> if:<ul><li>Anxiety or depression related to chronic obstructive pulmonary disease (COPD) are identified.</li><li>For more information, see the CKS topics on <a class="topic-reference external-reference" href="../../../depression/index.html">Depression</a> and <a class="topic-reference external-reference" href="../../../generalized-anxiety-disorder/index.html">Generalized anxiety disorder</a>.</li></ul></li></ul><!-- end field 84a7b6b4-2a43-4a80-9b9f-c644199b6ea6 --><!-- end item ada3ccc8-fd97-4425-b282-1da4d7b57d0b --></div><section aria-labelledby="basis-for-recommendation-835" class="ChapterBody-module--wrapper--2HCfk "><h5 id="basis-for-recommendation-835">Basis for recommendation</h5><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 83507058-7b3a-4a24-a508-23ed0b8ef8d2 --><!-- begin field d8b9b86c-3731-4903-82dd-f5fd1254dc3f --><p>The recommendations on referral to other members of the multidisciplinary team are based on the clinical guidelines <em>Managing malnutrition in COPD. Including a pathway for the appropriate use of ONS to support community healthcare professionals</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">RCGP, 2016</a>] and <em>Chronic obstructive pulmonary disease in over 16s: diagnosis and management</em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2019a</a>].</p><!-- end field d8b9b86c-3731-4903-82dd-f5fd1254dc3f --><!-- end item 83507058-7b3a-4a24-a508-23ed0b8ef8d2 --></div></section></section></section><section aria-labelledby="treatment" class="ChapterBody-module--wrapper--2HCfk "><h3 id="treatment">What treatment should I offer a person with COPD?</h3><section aria-labelledby="non-pharmacological-treatments-inhaled-treatments" class="ChapterBody-module--wrapper--2HCfk "><h4 id="non-pharmacological-treatments-inhaled-treatments">Non-pharmacological treatments and inhaled treatments</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 2696f117-f53f-4770-9b5b-0a3d969cc579 --><!-- begin field 132f96c9-44bd-4566-a0d7-86df4442560c --><ul><li><strong>In all people with confirmed COPD</strong><strong>:</strong><ul><li>Explain the diagnosis, risk factors for progression and the importance of a healthy diet and physical activity.Patient information is available from:<ul><li><a href="https://www.blf.org.uk/" target="_blank" rel="noopener" data-hyperlink-id="09d2c480-5569-4b8a-b3dd-ab1301235bd6">The British Lung Foundation</a>  <a href="https://www.blf.org.uk/support-for-you/copd" target="_blank" rel="noopener" data-hyperlink-id="26ba3867-b460-4340-849f-ab1301235c98">COPD (chronic obstructive pulmonary disease)</a>.</li><li><a href="https://www.nhs.uk/" target="_blank" rel="noopener" data-hyperlink-id="192c64e1-620c-4692-9252-ab1301235ca9">NHS</a>  <a href="https://www.nhs.uk/conditions/chronic-obstructive-pulmonary-disease-copd/" target="_blank" rel="noopener" data-hyperlink-id="14abcf00-523a-44b7-a2c4-ab1301235cc1">Chronic obstructive pulmonary disease (COPD</a><u>)</u>.</li></ul></li><li>At every opportunity, offer treatment and support to stop smoking (where applicable).<ul><li>For more information, see the CKS topic on <a class="topic-reference external-reference" href="../../../smoking-cessation/index.html">Smoking cessation</a>.</li></ul></li><li>Offer pneumococcal and influenza vaccinations.</li><li>Offer <a class="topic-reference internal-reference" href="index.html#referral-for-pulmonary-rehabilitation">pulmonary rehabilitation</a> if indicated.</li><li>Develop a <a class="topic-reference internal-reference" href="index.html#self-management-plan">personalised self-management plan</a> in conjunction with the person.</li><li>Optimise treatment for comorbidities.</li></ul></li><li><strong>If the person is breathless and has exercise limitation:</strong><ul><li><strong>Offer a </strong><a class="topic-reference internal-reference" href="../../prescribing-information/beta-2-agonists/index.html#dose-of-short-acting">short-acting beta-2 agonist</a><strong> (SABA)<em>or</em> <a class="topic-reference internal-reference" href="../../prescribing-information/muscarinic-antagonists/index.html">short-acting muscarinic antagonist</a>(SAMA)</strong>to use as needed to relieve breathlessness and improve exercise tolerance.</li><li>Take into account individual factors such as age, dexterity, coordination, and inspiratory flow when choosing a <a class="topic-reference internal-reference" href="index.html#delivery-systems">delivery system</a> for inhaled medication  ensure the person has appropriate training on use and can demonstrate satisfactory technique. For more information, see the section on <a class="topic-reference internal-reference" href="index.html#delivery-systems">delivery systems</a>.</li><li>Regularly review medication, adherence and inhaler technique.</li></ul></li><li><strong>If the person continues to be limited by symptoms or has exacerbations despite use of short-acting bronchodilators:</strong><ul><li><strong>Review to ensure that:</strong><ul><li>Non-pharmacological management is optimal and relevant vaccinations and smoking cessation support (if applicable) have been offered.</li><li>Symptoms are not due to <a class="topic-reference internal-reference" href="../../diagnosis/diagnosis-copd/index.html#differential-diagnosis">another condition</a>.</li></ul></li><li><strong>If they have <em>no</em> <a class="topic-reference internal-reference" href="index.html#basis-for-recommendation-d40">asthmatic features</a> or features suggestive of steroid responsiveness:</strong><ul><li>Offer a long-acting beta-2 agonist (LABA) plus a long-acting muscarinic antagonist (LAMA).</li><li>If the person continues to have day-to-day symptoms adversely affecting quality of life:<ul><li>Consider a 3 month trial of LABA plus LAMA plus inhaled corticosteroids (ICS).</li><li>If there is no improvement at 3 months change back to LABA plus LAMA.</li><li>If symptoms have improved, continue with LAMA plus LABA plus ICS and review at least annually.</li></ul></li></ul></li><li><strong>If they have <a class="topic-reference internal-reference" href="index.html#basis-for-recommendation-d40">asthmatic features</a> or features suggestive of steroid responsiveness:</strong><ul><li>Consider offering LABA plus ICS.<ul><li>If person continues to have day-to-day symptoms adversely affecting quality of life or has 1 severe (needing hospitalization) or 2 moderate exacerbations of COPD within a year, offer LABA plus LAMA plus ICS.</li></ul></li></ul></li></ul></li><li><strong>In people taking ICS for COPD:</strong><ul><li>Be aware of, and discuss the increased risks (including pneumonia) of these.</li><li>If treatment with an ICS is continued, ensure reasons are clearly documented.</li></ul></li><li><strong>If the person is currently using LABAs outside of recommendations above</strong> (such as LAMA or LABA monotherapy) and symptoms are well controlled, no change in treatment is required until clinical needs change.</li><li><strong>If the person is still limited by breathlessness or subject to frequent exacerbations consider the need for referral and/or add on treatments.</strong></li></ul><!-- end field 132f96c9-44bd-4566-a0d7-86df4442560c --><!-- end item 2696f117-f53f-4770-9b5b-0a3d969cc579 --></div><section aria-labelledby="basis-for-recommendation-d40" class="ChapterBody-module--wrapper--2HCfk "><h5 id="basis-for-recommendation-d40">Basis for recommendation</h5><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item d40dd5c5-59c7-43f4-8acc-6104d0f8ed63 --><!-- begin field aaa3ee8a-7c49-473d-95bd-9158e11d7d48 --><p>The recommendations on non-pharmacological and inhaled treatment for chronic obstructive pulmonary diseases (COPD) are largely based on the National Institute for Health and Care Excellence (NICE) guideline <em>Chronic obstructive pulmonary disease in over 16s: diagnosis and management</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2019b</a>] and the clinical guidelines <em>Diagnosis and initial treatment of asthma, COPD and asthma-COPD overlap</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">GINA and GOLD, 2017</a>], <em>COPD-X: concise guide for primary care</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Lung Foundation Australia, 2017</a>], <em>Evaluation of appropriateness of inhaled corticosteroid (ICS) therapy in COPD and guidance on ICS withdrawal </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Primary Care Respiratory Society, 2018</a>], and<em>All Wales COPD management and prescribing guideline</em> and <em>Global initiative for chronic obstructive lung disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2019 report</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">GOLD, 2019</a>], and expert opinion in review articles [<a class="bibliography-reference internal-reference" href="../../references/index.html">Gentry, 2017</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Rabe, 2017</a>].</p><p><strong>Non-pharmacological management </strong> guidance from NICE [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2019a</a>] and GOLD [<a class="bibliography-reference internal-reference" href="../../references/index.html">GOLD, 2019</a>] emphasise the importance of patient education on the condition, risk factors for progression and health-promoting behaviours in achieving optimal health outcomes.</p><ul><li>Smoking cessation is key to improving outcome  it can reduce progressive decline in lung function over time, exacerbations, delay onset of disability in addition to reducing smoking-related comorbidities (such as lung cancer and cardiovascular disease) [<a class="bibliography-reference internal-reference" href="../../references/index.html">Lung Foundation Australia, 2017</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Rabe, 2017</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">GOLD, 2019</a>] [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2019a</a>].</li><li>Vaccination  influenza vaccination reduces the incidence of lower respiratory tract infections (LRTIs) and the risk of mortality in people with COPD; pneumococcal vaccination decreases incidence of LRTIs [<a class="bibliography-reference internal-reference" href="../../references/index.html">Lung Foundation Australia, 2017</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">GOLD, 2019</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2019a</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">GOLD, 2019</a>].</li><li>Pulmonary rehabilitation  improves symptoms, health-related quality of life and exercise tolerance [<a class="bibliography-reference internal-reference" href="../../references/index.html">GOLD, 2019</a>].</li><li>Treatment of comorbidities  comorbidities influence mortality and hospitalizations independently and should be optimally treated to improve outcome [<a class="bibliography-reference internal-reference" href="../../references/index.html">GOLD, 2019</a>].</li></ul><p><strong>Inhaled therapies </strong> recommendations on inhaled therapies are taken from the NICE guideline <em>Chronic obstructive pulmonary disease in over 16s: diagnosis and management</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2019a</a>].</p><ul><li><strong>Short-acting bronchodilators </strong>(short-acting beta-2 agonists [SABA] and short-acting muscarinic antagonists [SAMA]).<ul><li>NICE guidance recommends that SABAsand SAMAsshould be used as necessary as initial empirical treatment for relief of breathlessness and exercise limitation in people with COPD.</li></ul></li><li><strong>Long-acting bronchodilators </strong>(long-acting beta-2 agonists [LABA] and long-acting muscarinic antagonists [LAMA]).<ul><li>The NICE guideline committee review of evidence found that compared to monotherapy and other dual therapy combinations, LAMA+LABA provided the greatest improvement in quality of life; was better at reducing the risk of moderate to severe exacerbations; and was the most cost-effective option.</li><li>Specific LAMAs were not recommended as evidence did not show any meaningful difference in effectiveness between different drugs in the class  instead drug and inhaler choice should be based on ease of use (for example minimising the number and types of inhalers prescribed).</li></ul></li><li><strong>Inhaled corticosteroids (ICS)</strong><ul><li>Several guidelines [<a class="bibliography-reference internal-reference" href="../../references/index.html">Lung Foundation Australia, 2017</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">GOLD, 2019</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2019a</a>] highlight the increased risk of pneumonia in people taking inhaled corticosteroids  this should be discussed this as part of a joint decision-making process when deciding on treatment.</li><li>The NICE guideline committee recommendation on the use of LABA+ICS in certain clinical situations is based on clinical experience and knowledge of the likely benefit of inhaled corticosteroids in specific COPD phenotypes.</li><li>Studies have reported conflicting results on withdrawal of ICS  some show an increase in exacerbations and/or symptoms while others do not [<a class="bibliography-reference internal-reference" href="../../references/index.html">GOLD, 2019</a>].</li></ul></li><li><strong>Asthmatic features/features suggesting steroid responsiveness</strong><ul><li>NICE guidance states that asthmatic features/features suggesting steroid responsiveness in this context include any previous secure diagnosis of asthma or atopy, a higher blood eosinophil count, substantial variation in FEV1 over time (at least 400 ml) or substantial diurnal variation in peak expiratory flow (at least 20%) [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2019a</a>].</li></ul></li></ul><p><strong>Triple therapy </strong> the NICE guidelinerecommends through clinical review (to exclude other conditions as a cause of persistent symptoms) before escalation of COPD treatment [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2019a</a>].</p><ul><li>For people currently taking LABA+ICS,evidence (reviewed by the NICE guideline development committee) showed that LAMA+LABA+ICS reduced the rate of severe exacerbations, improved FEV1, and did not increase the risk of pneumonia or other serious adverse events.</li><li>For people currently taking LAMA+LABA, the evidence showed that LAMA+LABA+ICS reduced the rate of serious exacerbations and led to some improvement in quality of life improvement  improvements less marked than in those taking LABA+ICS before starting triple therapy.<ul><li>People who switched from LAMA+LABA to triple therapy were more likely to get pneumonia  in those with less severe symptoms, it is less clear if triple therapy provides enough benefits to outweigh the risk of pneumonia.</li><li>A 3-month trial was recommended to help identify people with less severe symptoms who will benefit from triple therapy, while ensuring that those who do not benefit can easily switch back to LAMA+LABA and avoid the risks of triple therapy if no benefit is seen.</li></ul></li></ul><!-- end field aaa3ee8a-7c49-473d-95bd-9158e11d7d48 --><!-- end item d40dd5c5-59c7-43f4-8acc-6104d0f8ed63 --></div></section></section><section aria-labelledby="delivery-systems" class="ChapterBody-module--wrapper--2HCfk "><h4 id="delivery-systems">Delivery systems</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item ff009c94-c11f-41c8-8f34-c49888dacb99 --><!-- begin field 0a454372-7d41-4ab0-9b69-b1908cca3425 --><h5>Inhalers</h5><ul><li>For most people, bronchodilator therapy is best administered via a hand-held inhaler (and spacer where appropriate).<ul><li>Appropriate training is required to ensure adequate inhaler technique  repeated checks at follow up are also essential as poor technique, even after training, is common.</li><li>Assessment of inhaler technique and adherence to treatment should be carried out before concluding that a specific therapy is ineffective.</li></ul></li><li>Choice of inhalers should take into account effect on symptoms (including exacerbations), the person's preference and ability to use the inhalers, adverseeffects and cost.<ul><li>If a person cannot use a particular inhaler correctly or it is unsuitable for them provide an alternative.</li><li>Minimise the number and type of inhalers used by each person as much as possible  specifying the brand and inhaler in prescriptions will help ensure the person receives the same device each time.</li></ul></li></ul><h5>Spacers</h5><ul><li>Spacers are plastic devices with a mouthpiece at one end and a hole for a metered-dose inhaler (MDI) to be inserted at the other:<ul><li>They require less coordination than use of a MDI alone and allow carers to help people with cognitive impairment or functional problems.</li><li>They slow down the particles of the drug and allow more time for evaporation of the propellant, so that more of the drug can be inhaled.</li><li>They increase the proportion of the drug delivered to the airways and reduce the amount of drug deposited in the oropharynx (thereby reducing local adverse effects and systemic absorption).</li><li>They are useful in people with poor inhalation technique.</li></ul></li><li>Provide a spacer that is compatible with the person's metered-dose inhaler  spacers are not interchangeable and must be compatible with the MDI used.</li><li>Advise people to use a spacer with a MDI metered-dose inhaler in the following way:<ul><li>Administer the drug by single actuations of the metered-dose inhaler into the spacer, inhaling after each actuation.</li><li>There should be minimal delay between inhaler actuation and inhalation.</li><li>Normal tidal breathing can be used as it is as effective as single breaths.</li><li>Repeat if a second dose is required.</li></ul></li><li>Advise people on spacer cleaning:<ul><li>Do not clean the spacer more than monthly, because more frequent cleaning affects their performance (because of a build-up of static).</li><li>Hand wash using warm water and washing-up liquid, and allow the spacer to air dry.</li></ul></li></ul><h5>Nebulisers</h5><ul><li>Consider nebuliser therapy for people with distressing or disabling breathlessness despite maximal therapy using inhalers.<ul><li><a class="topic-reference internal-reference" href="index.html#referral-to-a-respiratory-specialist">Referral</a> for assessment by a respiratory specialist may be required before prescribing nebulizers.</li><li>Nebulised therapy should not be prescribed without an assessment of the person's and/ or carer's ability to use it.</li><li>Warn people using nebulized bronchodilators that it is dangerous to exceed the prescribed dose, and that they must seek medical advice if there is no response to their usual dose  doses of bronchodilators given by nebulization are usually much higher than from inhalers.</li><li>Use a nebuliser system that is known to be efficient and offer a choice between a facemask and a mouthpiece to administer therapy, unless the drug specifically requires a mouthpiece (for example, anticholinergic drugs).</li><li>For people with hypercapnia, the nebulizer should be driven by air. If oxygen is required, it should be given simultaneously by nasal cannula.</li><li>If nebuliser therapy is prescribed, provide the person with equipment, servicing, and ongoing advice and support.</li></ul></li><li>Only continue with a nebulizer if the person experiences at least one of the following:<ul><li>A reduction in symptoms.</li><li>An increase in the ability to undertake activities of daily living.</li><li>An increase in exercise capacity.</li><li>An improvement in lung function.</li></ul></li></ul><!-- end field 0a454372-7d41-4ab0-9b69-b1908cca3425 --><!-- end item ff009c94-c11f-41c8-8f34-c49888dacb99 --></div><section aria-labelledby="basis-for-recommendation-381" class="ChapterBody-module--wrapper--2HCfk "><h5 id="basis-for-recommendation-381">Basis for recommendation</h5><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 381ef964-b213-4cec-a794-108ef1f4f5f8 --><!-- begin field 700700ac-400e-4dca-bb95-b75a4061ce1b --><p>The information on devices and delivery systems is based on the <em>Global initiative for chronic obstructive lung disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2019 report</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">GOLD, 2019</a>], andthe National Institute for Health and Care Excellence (NICE) guideline<em>Chronic obstructive pulmonary disease in over 16s: diagnosis and management</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2019a</a>].</p><!-- end field 700700ac-400e-4dca-bb95-b75a4061ce1b --><!-- end item 381ef964-b213-4cec-a794-108ef1f4f5f8 --></div></section></section><section aria-labelledby="add-on-treatments" class="ChapterBody-module--wrapper--2HCfk "><h4 id="add-on-treatments">What add on treatments can be considered in chronic obstructive pulmonary disease (COPD)?</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item fcac23df-0d45-4b64-99ec-fe7a71f30dfa --><!-- begin field 6edd480d-3421-4c3e-bb3b-e417436ee708 --><ul><li><strong>Oral corticosteroids</strong><ul><li>Do <strong><em>not</em></strong> start oral corticosteroids for maintenance treatment of COPD in primary care.<ul><li><a class="topic-reference internal-reference" href="index.html#referral-to-a-respiratory-specialist">Referral</a> to a respiratory specialist is required if long-term treatment is being considered.</li><li>People on long-term oral corticosteroid therapy should be monitored for osteoporosis and appropriate prophylaxis prescribed.</li></ul></li><li>For more information on oral corticosteroids and osteoporosis, see the CKS topics on <a class="topic-reference external-reference" href="../../../corticosteroids-oral/index.html">Corticosteroids - oral</a> and <a class="topic-reference external-reference" href="../../../osteoporosis-prevention-of-fragility-fractures/index.html">Osteoporosis - prevention of fragility fractures</a>.</li></ul></li><li><strong>Oral theophylline (slow release)</strong><ul><li>Oral theophylline should only be considered after a trial of short-acting and long-acting bronchodilators, <em>or</em> for people who cannot use inhaled therapy  consider discussing with a respiratory specialist.<ul><li>Plasma levels and interactions must be monitored and doses adjusted appropriately.</li><li>Particular caution is required if prescribing theophylline to older people due to differences in pharmacokinetics, increased incidence of comorbidities and interactions with multiple other medications.</li></ul></li><li>If prescribed, assess effectiveness of theophylline by improvements in symptoms, activities of daily living, exercise capacity and lung function.</li><li>The dose of theophylline should be reduced in people prescribed macrolide or fluoroquinolone antibiotics (or other drugs known to interact) for an exacerbation.</li></ul></li><li><strong>Oral mucolytic therapy</strong><ul><li>Consider mucolytic therapy if a person with stable COPD develops a chronic cough productive of sputum.<ul><li>Only continue the mucolytic if there is symptomatic improvement (such as reduction in frequency of cough and sputum production).</li><li>Mucolytics should not be used routinely to prevent exacerbations in people with stable COPD.</li></ul></li></ul></li><li><strong>Oral anti-tussive therapy</strong><ul><li>Do not use anti-tussive therapy in the management of stable COPD.</li></ul></li><li><strong>Oral prophylactic antibiotic therapy</strong><ul><li>Refer to/discuss with a respiratory specialist if oral prophylactic antibiotic therapy is being considered.</li><li>There are strict criteria for use of prophylactic antibiotics in COPD  thorough assessment (including imaging) to exclude other possible causes of symptoms (such as TB, antibiotic resistant organisms and bronchiectasis) prior to prescription is indicated.</li></ul></li><li><strong>Prophylactic antibiotic treatment initiated in secondary care</strong><ul><li>For people with COPD who have had more than three exacerbations requiring steroid therapy and at least one exacerbation requiring hospital admission in the previous year you should consider referral to a specialist in respiratory medicine to consider prophylactic oral macrolide therapy.</li><li>Macrolides should only be started following discussion and shared decision-making between the patient and a respiratory specialist.</li><li style="box-sizing: inherit;">Treatment with azithromycin 500 mg three times per week, should be considered for a minimum of 612 months to assess evidence of efficacy in reducing exacerbations.</li></ul></li><li><strong>Before commencing prophylactic oral macrolides</strong><ul><li>Optimise non-pharmacological and pharmacological therapies, including smoking cessation, optimised inhaler technique, optimised self-management care plan, airway clearance techniques, and attendance at pulmonary rehabilitation course.</li><li>Perform ECG (electrocardiogram) to assess QTc interval.</li><li>Perform baseline liver function tests.</li><li>Counsel people with COPD about potential adverse effects, including gastrointestinal upset, hearing and balance disturbance, cardiac effects, and microbiological resistance.</li><li>Arrange microbiological assessment of sputum before therapy, including investigation for non-tuberculous mycobacteria (NTM). Macrolide monotherapy should be avoided if an NTM is identified. Repeat assessments are recommended with clinical decline or during exacerbations to monitor resistance patterns.</li><li>Consider accurate assessment of baseline exacerbation rate and a CT scan to exclude a possible diagnosis of bronchiectasis.</li></ul></li><li><strong>After starting oral macrolides</strong><ul><li>If adverse gastrointestinal effects occur at this higher dose of azithromycin clinicians can consider a dose reduction to 250 mg three times per week.</li><li>Liver function tests should be checked 1 month after starting treatment and then every 6 months. An ECG should be performed 1 month after starting treatment to check for new QTc prolongation. If present, treatment should be stopped.</li><li>Subsequent follow up at 6 and 12 months should determine whether benefit is being derived from therapy by using objective measures such as the exacerbation rate, CAT score or quality of life as measured by a validated assessment tool. If there is no benefit treatment should be stopped.</li><li>It is not necessary to stop prophylactic azithromycin during an acute exacerbation of COPD unless another antibiotic with potential to affect the QT interval has also been prescribed.</li></ul></li><li><strong>Oral phosphodiesterase-4 inhibitors</strong><ul><li>May be considered for severe disease with persistent symptoms and exacerbations despite optimal inhaled and non-pharmacological therapy.</li><li>Must be initiated by a respiratory specialist  <a class="topic-reference internal-reference" href="index.html#referral-to-a-respiratory-specialist">referral</a> is indicated.</li></ul></li></ul><!-- end field 6edd480d-3421-4c3e-bb3b-e417436ee708 --><!-- end item fcac23df-0d45-4b64-99ec-fe7a71f30dfa --></div><section aria-labelledby="basis-for-recommendation-879" class="ChapterBody-module--wrapper--2HCfk "><h5 id="basis-for-recommendation-879">Basis for recommendation</h5><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 8790c7cd-9413-4272-9f9a-1c863bd0c732 --><!-- begin field ccb1b11b-f75a-4a79-81c0-7ed66b2f5426 --><p>The recommendations on additional oral treatments for stable COPD are based on the National Institute for Health and Care Excellence (NICE) guideline C<em>hronic obstructive pulmonary disease in over 16s: diagnosis and management</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2019a</a>], the clinical guideline <em>Global initiative for chronic obstructive lung disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2019 report</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">GOLD, 2019</a>], and expert opinion in review articles [<a class="bibliography-reference internal-reference" href="../../references/index.html">Gentry, 2017</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Rabe, 2017</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Wedzicha, 2017b</a>].</p><h6>Oral corticosteroids</h6><ul><li>Long-term oral corticosteroid therapy in COPD is not usually recommended. However, NICE guidance states that in some people with advanced COPD long-term oral corticosteroids may be needed if these cannot be withdrawn after an exacerbation  in this situation, the dose should be kept as low as possible [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2019a</a>].</li></ul><h6>Theophylline</h6><ul><li>Theophylline has been used for many years to treat COPD, however, because of potential toxicity, the need for monitoring plasma levels and significant interactions with other drugs it is no longer considered initial empirical treatment [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2019a</a>].</li><li>Clinical guidance from GOLD recommends that theophylline is not used unless other long-term treatment bronchodilators are unavailable or unaffordable [<a class="bibliography-reference internal-reference" href="../../references/index.html">GOLD, 2019</a>].</li></ul><h6>Oral mucolytic therapy</h6><ul><li>Mucolytics are thought to increase expectoration of sputum by reducing its viscosity.</li><li>Recommendations on use of oral mucolytic therapy are taken from NICE guidance  routine use primarily for prevention of exacerbations is not recommended as evidence is limited [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2019a</a>].</li></ul><h6>Oral antitussive therapy</h6><ul><li>Guidance from NICE and GOLD recommend that antitussives should not be used [<a class="bibliography-reference internal-reference" href="../../references/index.html">GOLD, 2019</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2019a</a>].</li></ul><h6>Oral prophylactic antibiotic therapy</h6><ul><li>NICE guidance recommends considering the need for respiratory specialist input if prophylactic antibiotic therapy is being considered. Azithromycin may be indicated if the person is symptomatic and has frequent severe exacerbations with sputum production and non-pharmacological and inhaled therapies have been optimized. Further assessment including sputum culture and CT thorax is indicated prior to initiation of prophylactic antibiotic therapy [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2019a</a>].</li><li>The recommendation to consider referral for long-term oral macrolides in people who have had three or more exacerbations and an admission to hospital in the previous year is based on the <em>British Thoracic Society Guideline for the use of long-term macrolides in adults with respiratory disease</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Smith, 2020</a>].</li></ul><h6>Oral phosphodiesterase-4 inhibitors</h6><ul><li>NICE guidance [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2017</a>] recommends that roflumilast (as an add-on to bronchodilator therapy) is an option for treating severe COPD only if:<ul><li>Disease is severe (forced expiratory volume in 1 second [FEV1] after a bronchodilator of less than 50% of predicted normal), and</li><li>The person has had 2 or more exacerbations in the previous 12 months despite triple inhaled therapy with a long-acting muscarinic antagonist, a long-acting beta-2 agonist and an inhaled corticosteroid.</li></ul></li><li>Treatment with roflumilast should be started by a specialist in respiratory medicine [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2019a</a>].</li></ul><!-- end field ccb1b11b-f75a-4a79-81c0-7ed66b2f5426 --><!-- end item 8790c7cd-9413-4272-9f9a-1c863bd0c732 --></div></section></section></section><section aria-labelledby="self-management-plan" class="ChapterBody-module--wrapper--2HCfk "><h3 id="self-management-plan">What information should self-management plans offer for people with COPD?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 44785f8f-0dd7-41e2-b7e4-8a95fb4d9f62 --><!-- begin field 3cf179a5-9bdc-4c45-861c-7aa0b2d0528b --><ul><li>Self-management plans should be developed in collaboration with each person with COPD and their family members/carers (where appropriate) and provide personalized information and advice on:<ul><li>COPD and its symptoms.</li><li>Non-pharmacological measures including diet, physical activity, pulmonary rehabilitation, smoking cessation and avoidance of passive smoking (where relevant).</li><li>The importance of vaccinations.</li><li>Appropriate use of inhaled therapies (including inhaler technique and the importance of adherence).</li><li>Early recognition and management of exacerbations including:<ul><li>How to adjust short-acting bronchodilator therapy to treat symptoms, and if there is no response, when to contact a healthcare professional.</li><li>When to take short courses of oral corticosteroids and antibiotics prescribed to keep at home for exacerbations and when to contact ahealthcare professional.</li></ul></li><li>Details of local and national organisations and online resources that can provide more information and support such as the <a data-hyperlink-id="74d24f8d-19e6-42df-a96f-ab130129ee0e" href="https://www.blf.org.uk/" target="_blank">British Lung Foundation</a> which has <a data-hyperlink-id="e2991ed1-fe4c-4392-a302-ab130129eebb" href="https://www.blf.org.uk/support-for-you/copd" target="_blank">patient guides</a> on COPD.</li></ul></li><li>Review self-management plans regularly.</li></ul><!-- end field 3cf179a5-9bdc-4c45-861c-7aa0b2d0528b --><!-- end item 44785f8f-0dd7-41e2-b7e4-8a95fb4d9f62 --></div><section aria-labelledby="basis-for-recommendation-429" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-429">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 429acc7f-100f-421d-a5e0-9607f5ca99b8 --><!-- begin field 8a8af197-8556-4a22-969a-b985083e936e --><p>The recommendations on providing a self-management plan for people with chronic obstructive pulmonary disease (COPD) are largely based on the National Institute for Health and Care Excellence (NICE) guideline <em>Chronic obstructive pulmonary disease in over 16s: diagnosis and management</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2019a</a>], the clinical guideline <em>COPD-X: concise guide for primary care</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Lung Foundation Australia, 2017</a>], <em>Chronic obstructive pulmonary disease (COPD): best practice guide</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Scottish Government, 2017</a>], and <em>Global initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2019 repor</em>t [<a class="bibliography-reference internal-reference" href="../../references/index.html">GOLD, 2019</a>].</p><ul><li>NICE [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2019a</a>]recommends offering people a short course of oral corticosteroids and a short course of oral antibiotics to keep at home as part of their exacerbation action plan if:<ul><li>They have had an exacerbation within the last year, and are at continued risk of exacerbations.</li><li>They understand and are confident about when and how to take prescribed medicines, and are aware of the associated risks and benefits.</li><li>They know to tell their healthcare professional when they have used the medicines, and to ask for replacements.</li></ul></li><li>Expert opinion of previous external reviewers is that people with COPD who have a supply of rescue medications at home should contact a primary healthcare professional when they start treatment to ensure that medications are taken appropriately, to record the exacerbation, to attempt to identify any trigger for the exacerbation, and to allow replacement of a home supply of rescue medication.</li></ul><!-- end field 8a8af197-8556-4a22-969a-b985083e936e --><!-- end item 429acc7f-100f-421d-a5e0-9607f5ca99b8 --></div></section></section><section aria-labelledby="advice" class="ChapterBody-module--wrapper--2HCfk "><h3 id="advice">What advice should I give to a person with COPD?</h3><section aria-labelledby="advice-about-flying" class="ChapterBody-module--wrapper--2HCfk "><h4 id="advice-about-flying">What should I advise a person with COPD about air travel?</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 9f11f14a-a427-4063-ad7d-f94e0281e308 --><!-- begin field 565f9be7-8b4a-4248-acb7-e104e2b69c39 --><p>For up to date, detailed guidance on air travel for people with respiratory disease for health professionals see the <a data-hyperlink-id="c1292a21-44d8-49d2-b13b-ab13012baca3" href="https://www.brit-thoracic.org.uk/" target="_blank">British Thoracic Society</a> and <a data-hyperlink-id="faa771dc-c334-45bb-b9cb-ab13012bacca" href="https://www.caa.co.uk/home/" target="_blank">Civil Aviation Authority</a> websites.</p><ul><li>In general, COPD should be stable and the person fully recovered from any exacerbation before considering flying. The British Thoracic Society recommends pre-flight respiratory assessment if the person has:<ul><li>Significant respiratory symptoms (dyspnoea, confusion) on previous air travel.</li><li>Severe COPD (FEV1 less than 30% predicted).</li><li>Bullous lung disease  people with bullous disease should be warned that risk of pneumothorax may be increased during air travel.</li><li>Comorbid conditions that are worsened by hypoxia such as cerebrovascular disease, cardiac disease or pulmonary hypertension.</li><li>Recently been discharged (within 6 weeks) following admission for acute respiratory illness.</li><li>Recent pneumothorax  air travel is contraindicated in people with ongoing pneumothorax with persistent air leak.</li><li>Risk of or previous venous thromboembolism.</li><li>Pre-existing requirement for oxygen, CPAP or ventilator support  air travel is contraindicated in people with a usual oxygen requirement exceeding a flow rate of 4 litres/minute at sea level.</li></ul></li><li>If uncertain about a persons safety to fly, refer to/discuss with a respiratory specialist the need for further assessment (for example a <a class="topic-reference internal-reference" href="index.html#secondary-care-assessments">walk test</a> and/or a <a class="topic-reference internal-reference" href="index.html#secondary-care-assessments">hypoxic challenge test</a><u>)</u>.</li><li>It should be made clear that the person takes responsibility for deciding to fly and that the airline can refuse carriage if the passengers safety is in doubt.<ul><li>Resting oxygen saturations and FEV1 do not reliably predict hypoxaemia or complications of air travel in people with respiratory disease.</li><li>FEV1 and oxygen saturations at sea level are not helpful in predicting who may be at risk of complications of flying.</li><li>Patient information is available from the <a data-hyperlink-id="ec4ebd83-9175-4a42-95e3-ab13012bacf3" href="http://www.brit-thoracic.org/" target="_blank">British Thoracic Society</a>.</li></ul></li><li>Advise all people with COPD that they should:<ul><li>Carry inhalers and other appropriate medication in their hand luggage  a doctors letter may be required.</li><li>Inform the airline of their condition and book extra services (such as supplemental oxygen, wheelchairs for transport to and from the aircraft) in advance  a fee may be changed.</li><li>Arrange medical insurance.</li><li>Keep well-hydrated and mobile.</li><li>Avoid smoking before, and alcohol before and during air travel.</li></ul></li></ul><!-- end field 565f9be7-8b4a-4248-acb7-e104e2b69c39 --><!-- end item 9f11f14a-a427-4063-ad7d-f94e0281e308 --></div><section aria-labelledby="secondary-care-assessments" class="ChapterBody-module--wrapper--2HCfk "><h5 id="secondary-care-assessments">Secondary care assessments</h5><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 6543ed62-d1e0-4118-9304-b55caae64a8d --><!-- begin field 678193ed-c037-496b-b15d-8dec3ac7b563 --><ul><li><strong>The walk test:</strong><ul><li>Involves asking the person to walk for a standardised length of time (usually 6 or 12 minutes).</li><li>Failure to complete the test and/or moderate to severe respiratory distress measured on a visual analogue scale indicates a possible need for in-flight oxygen.</li></ul></li></ul><ul><li><strong>The hypoxic challenge test:</strong><ul><li>Is performed in a specialist lung function unit and is used to assess whether a person needs in-flight oxygen.</li><li>Measures the person's response to a simulated aircraft cabin environment.</li><li>In this investigation, 15% oxygen is administered and the person is monitored continuously by pulse oximetry.</li><li>A partial pressure of arterial oxygen (PaO2) of 6.6 kPa or an oxygen saturation of 85% is used as the cut-off value below which supplemental oxygen is recommended for air travel.</li></ul></li></ul><!-- end field 678193ed-c037-496b-b15d-8dec3ac7b563 --><!-- end item 6543ed62-d1e0-4118-9304-b55caae64a8d --></div></section><section aria-labelledby="basis-for-recommendation-5ed" class="ChapterBody-module--wrapper--2HCfk "><h5 id="basis-for-recommendation-5ed">Basis for recommendation</h5><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 5ed1fb5e-82ee-4e00-9d8b-ada685a0d4a8 --><!-- begin field e05fb67a-28e2-47a8-91a0-8d157f19be9b --><p>At the time of writing the British Thoracic Society (BTS) Clinical Statement on Air Travel wasin the process of being updated  recommendations are based on the available 2011 BTS clinical guidance <em>Managing passengers with stable respiratory disease planning air travel: British Thoracic Society recommendations</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">British Thoracic Society, 2011</a>].</p><h6>Fitness to fly assessment</h6><p>The recommendations on the fitness to fly assessment in primary care are based on information from the British Thoracic Society (BTS) guideline <em>Managing passengers with stable respiratory disease planning air travel</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">British Thoracic Society, 2011</a>] and the Civil Aviation Authority (CAA) [<a class="bibliography-reference internal-reference" href="../../references/index.html">Civil Aviation Authority, 2015</a>].</p><ul><li>The BTS identifies people with a forced expiratory volume in 1 second (FEV1) of less than 30% predicted, and those with pulmonary hypertension, as requiring assessment with a history and examination as a minimum.</li><li>The CAA states that assessment of whether a person can walk 50 m or climb a flight of stairs without significant breathlessness is the single, most practical fitness to fly test [<a class="bibliography-reference internal-reference" href="../../references/index.html">Civil Aviation Authority, 2015</a>].</li><li>The BTS states that neither resting sea-level oxygen saturations, nor FEV1 in those with respiratory disease accurately predict hypoxaemia or complications during air travel.</li><li>Hypoxic challenge test and walk tests  the information on these tests is taken from the BTS guidance.</li></ul><!-- end field e05fb67a-28e2-47a8-91a0-8d157f19be9b --><!-- end item 5ed1fb5e-82ee-4e00-9d8b-ada685a0d4a8 --></div></section></section><section aria-labelledby="advice-about-driving" class="ChapterBody-module--wrapper--2HCfk "><h4 id="advice-about-driving">What should I advise a person with COPD about driving?</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 7e203c89-7919-4c19-9f6b-9664d6ae4246 --><!-- begin field f712687a-c343-4fb1-9161-9599fcd1b83c --><ul><li>For both group 1 (car or motorcycle) or group 2 (lorry or bus) entitlement:<ul><li>The Driver and Vehicle Licensing Agency (DVLA) need not be informed unless any complications are associated with cough syncope, disabling dizziness, fainting or loss of consciousness.</li><li>If the DVLA needs to be notified, advise the person that it is their responsibility to do so.</li></ul></li><li>For detailed, up-to-date information, see the DVLA document <a data-hyperlink-id="35d2257a-51a5-4e88-af56-ab13012d133c" href="https://www.gov.uk/government/publications/assessing-fitness-to-drive-a-guide-for-medical-professionals" target="_blank">Assessing fitness to drive: a guide for medical professionals</a> for more information.</li></ul><!-- end field f712687a-c343-4fb1-9161-9599fcd1b83c --><!-- end item 7e203c89-7919-4c19-9f6b-9664d6ae4246 --></div><section aria-labelledby="basis-for-recommendation-a56" class="ChapterBody-module--wrapper--2HCfk "><h5 id="basis-for-recommendation-a56">Basis for recommendation</h5><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item a56316d3-dda0-4b2f-a916-951c49492784 --><!-- begin field 3ed2e8ef-36fb-4b4a-a582-fcd49b25fb5b --><p>The information on medical rules for driving is based on the Driver and Vehicle Licensing Agency's guidance <a href="https://www.gov.uk/government/publications/assessing-fitness-to-drive-a-guide-for-medical-professionals" target="_blank" data-hyperlink-id="4412c28b-db27-4e5b-a10d-ab13012d6c5c"><em>Assessing fitness to drive: a guide for medical professionals</em></a>.</p><!-- end field 3ed2e8ef-36fb-4b4a-a582-fcd49b25fb5b --><!-- end item a56316d3-dda0-4b2f-a916-951c49492784 --></div></section></section></section><section aria-labelledby="follow-up" class="ChapterBody-module--wrapper--2HCfk "><h3 id="follow-up">How should I follow up a person with COPD?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 3a294ce0-0bb6-42dd-8738-f18ca3b11e8c --><!-- begin field 85c80b25-16e8-4b28-9268-0fb5e3e3627d --><ul><li><strong>Frequency of follow up</strong><ul><li>Review people with mild (forced expiratory volume in 1 second [FEV1] at least 80% of predicted value), moderate (FEV1 5079% of predicted value), or severe (FEV1 3049% of predicted value) COPD at least once a year.</li><li>Review people with very severe COPD (FEV1 less than 30% of predicted value <em>or</em> FEV1 less than 50% with respiratory failure) at least twice a year.</li><li>Specialists should arrange regular review of people with severe COPD who require interventions such as long-term non-invasive ventilation.</li></ul></li><li><strong>In all people with COPD, at review:</strong><ul><li>Assess adequacy of symptom control and impact of COPD on life including:<ul><li>Severity of symptoms (using the Medical Research Council [MRC] dyspnoea scale).</li><li>Exacerbation frequency and severity (including hospitalizations and treatment required).</li><li>Consider the possibility of <a class="topic-reference internal-reference" href="../../diagnosis/diagnosis-copd/index.html#differential-diagnosis">alternative causes</a> for symptoms (for example asthma, bronchiectasis or lung cancer)  arrange further management as appropriate.</li></ul></li><li>Review current medications  check inhaler technique, adherence and adverse effects.</li><li>Record smoking status and body mass index  offer smoking cessation support where appropriate and consider the need for nutritional support.</li><li>Ensure that all people with COPD have been offered an annual influenza vaccination and a once-only pneumococcal vaccination.</li><li>Assess for <a class="topic-reference internal-reference" href="../../background-information/complications/index.html">complications</a> (such as cor pulmonale) or comorbidities (such as obstructive sleep apnoea, lung cancer, cardiovascular disease, osteoporosis, anxiety and depression).</li><li>Carry out spirometry  to identify decline in FEV1 and forced vital capacity (FVC).<ul><li>Record absolute and percent predicted values.</li><li>A loss of 500 ml or more over 5 years indicates rapidly progressing disease  consider the need for <a class="topic-reference internal-reference" href="index.html#referral-to-a-respiratory-specialist">specialist referral</a> and investigation.</li></ul></li><li>Consider the need for further investigations, <a class="topic-reference internal-reference" href="index.html#referral">referral</a> to a respiratory specialist, for pulmonary rehabilitation, or for social services and occupational therapy input.</li></ul></li><li><strong>In people with very severe COPD, also assess the following at review:</strong><ul><li>Oxygen saturation using pulse oximetry  consider the need for <a class="topic-reference internal-reference" href="index.html#referral-to-a-respiratory-specialist">referral to a respiratory specialist</a> for assessment for oxygen therapy.</li></ul></li><li><strong>Adjust treatment based on symptoms and exacerbations.</strong><ul><li>Consider the need for referral to secondary care for consideration of additional therapies (such as roflumilast or long-term antibiotics).</li></ul></li></ul><!-- end field 85c80b25-16e8-4b28-9268-0fb5e3e3627d --><!-- end item 3a294ce0-0bb6-42dd-8738-f18ca3b11e8c --></div><section aria-labelledby="basis-for-recommendation-5fd" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-5fd">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 5fd66f15-f2a7-47d6-8255-9d9b577005bc --><!-- begin field f0b963a9-872a-4a96-b0da-e94126a60a4f --><p>The recommendations on follow-up of people with chronic obstructive pulmonary disease (COPD) are largely based on the NICE clinical guideline <em>Chronic obstructive pulmonary disease in over 16s: diagnosis and management</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2019a</a>] and guidance from <em>COPD-X: concise guide for primary care</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Lung Foundation Australia, 2017</a>], and <em>Global initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2019 repor</em>t [<a class="bibliography-reference internal-reference" href="../../references/index.html">GOLD, 2019</a>].</p><!-- end field f0b963a9-872a-4a96-b0da-e94126a60a4f --><!-- end item 5fd66f15-f2a7-47d6-8255-9d9b577005bc --></div></section></section></section></div></div></div><div class="BackToTop-module--wrapper--2Z0EU"><nav aria-labelledby="back-to-top-link" class="BackToTop-module--nav--1DPZ6"><a class="BackToTop-module--anchor--1Nia6" id="back-to-top-link" href="index.html#content-start"><div class="container"><svg width="1em" height="1em" viewBox="0 0 512 512" fill="none" class="icon" aria-hidden="true" focusable="false"><path d="M478.152 338.576c0 10.091-3.525 18.661-10.576 25.712l-21.424 21.424c-7.243 7.243-15.909 10.864-26 10.864-10.283 0-18.853-3.621-25.712-10.864L255.576 247.136 116.712 385.712c-6.859 7.243-15.429 10.864-25.712 10.864s-18.853-3.621-25.712-10.864l-21.424-21.424C36.621 357.429 33 348.859 33 338.576c0-10.091 3.621-18.757 10.864-26l186-186c7.051-7.051 15.621-10.576 25.712-10.576 9.909 0 18.576 3.525 26 10.576l185.712 186c7.243 7.243 10.864 15.909 10.864 26z" fill="currentColor"></path></svg> Back to top</div></a></nav></div></main><footer class="Footer-module--footer--2QrGZ"><div class="Footer-module--container--1iuoB"><a href="https://www.nice.org.uk/" class="Footer-module--logo--3DGKv" aria-label="Go to NICE home page"></a><nav class="Services-module--wrapper--2qOoE" aria-label="Our services"><ul class="Services-module--list--3SZQu"><li><a href="https://pathways.nice.org.uk/" class="Services-module--link--2y_1q">NICE Pathways</a></li><li><a href="https://www.nice.org.uk/guidance" class="Services-module--link--2y_1q">NICE guidance</a></li><li><a href="https://www.nice.org.uk/standards-and-indicators" class="Services-module--link--2y_1q">Standards and indicators</a></li><li><a href="https://www.evidence.nhs.uk/" class="Services-module--link--2y_1q">Evidence search</a></li><li><a href="https://bnf.nice.org.uk/" class="Services-module--link--2y_1q"><abbr title="British National Formulary">BNF<!-- --> <span class="Services-module--visuallyHidden--t9mfm">British National Formulary</span></abbr><span aria-hidden="true" class="Services-module--tooltip--pg3nW">British National Formulary</span></a></li><li><a href="https://bnfc.nice.org.uk/" class="Services-module--link--2y_1q"><abbr title="British National Formulary for Children">BNFC<!-- --> <span class="Services-module--visuallyHidden--t9mfm">British National Formulary for Children</span></abbr><span aria-hidden="true" class="Services-module--tooltip--pg3nW">British National Formulary for Children</span></a></li><li><a href="../../../../index.html" aria-current="true" class="Services-module--link--2y_1q"><abbr title="Clinical Knowledge Summaries">CKS<!-- --> <span class="Services-module--visuallyHidden--t9mfm">Clinical Knowledge Summaries</span></abbr><span aria-hidden="true" class="Services-module--tooltip--pg3nW">Clinical Knowledge Summaries</span></a></li><li><a href="https://www.nice.org.uk/about/what-we-do/evidence-services/journals-and-databases" class="Services-module--link--2y_1q">Journals and databases</a></li></ul></nav><nav class="Pages-module--wrapper--30REl"><ul class="Pages-module--list--vvSk4"><li><a href="https://www.nice.org.uk/about">About NICE</a></li><li><a href="https://www.nice.org.uk/about/what-we-do/into-practice">Into practice</a></li><li><a href="https://www.nice.org.uk/get-involved">Get involved with NICE</a></li><li><a href="https://www.nice.org.uk/get-involved/jobs">Jobs</a></li><li><a href="https://www.nice.org.uk/news">News</a></li><li><a href="https://www.nice.org.uk/news/nice-newsletters-and-alerts">Newsletters and alerts</a></li><li><a href="https://www.nice.org.uk/get-involved/contact-us">Contact us</a></li><li><a href="https://www.nice.org.uk/leave-feedback">Leave feedback</a></li><li><a href="https://www.nice.org.uk/re-using-our-content">Reusing our content</a></li><li><a href="https://www.nice.org.uk/re-using-our-content/uk-open-content-licence">NICE UK Open Content Licence</a></li><li><a href="https://www.nice.org.uk/about/what-we-do/nice-syndication-api">Syndicate our content</a></li></ul></nav><div class="Social-module--wrapper--2nKsd"><ul class="Social-module--list--E5R5J" aria-label="NICE on social media"><li><a href="https://en-gb.facebook.com/NationalInstituteforHealthandCareExcellence/">Facebook</a></li><li><a href="https://twitter.com/NICEcomms">Twitter</a></li><li><a href="https://www.youtube.com/user/NICEmedia">YouTube</a></li><li><a href="https://www.instagram.com/nicecomms/">Instagram</a></li><li><a href="https://www.linkedin.com/company/national-institute-for-health-and-clinical-excellence">LinkedIn</a></li></ul></div></div><div class="Legal-module--wrapper--3AYMO"><div class="Legal-module--container--3TTBh"><nav class="Legal-module--menu--1e1Iy" aria-label="Legal menu"><ul><li><a href="https://www.nice.org.uk/accessibility">Accessibility</a></li><li><a href="https://www.nice.org.uk/freedom-of-information">Freedom of information</a></li><li><a href="https://www.nice.org.uk/glossary">Glossary</a></li><li><a href="https://www.nice.org.uk/terms-and-conditions">Terms and conditions</a></li><li><a href="https://www.nice.org.uk/privacy-notice">Privacy notice</a></li><li><a href="https://www.nice.org.uk/cookies">Cookies</a></li></ul></nav><p class="Legal-module--copyright--34nsI"><!-- --> <abbr title="National Institute for Health and Care Excellence">NICE</abbr> <!-- -->2021<!-- -->. All rights reserved. Subject to<!-- --> <a href="https://www.nice.org.uk/terms-and-conditions#notice-of-rights">Notice of rights</a>.</p></div></div></footer></div><div id="gatsby-announcer" style="position:absolute;top:0;width:1px;height:1px;padding:0;overflow:hidden;clip:rect(0, 0, 0, 0);white-space:nowrap;border:0" aria-live="assertive" aria-atomic="true"></div></div><script id="gatsby-script-loader">/*<![CDATA[*/window.pagePath="/topics/chronic-obstructive-pulmonary-disease/management/stable-copd/";/*]]>*/</script><script id="gatsby-chunk-mapping">/*<![CDATA[*/window.___chunkMapping={"polyfill":["/polyfill-2cb897c2a056d28c9332.js"],"app":["/app-53a71c38b210970893c4.js"],"component---cache-caches-gatsby-plugin-offline-app-shell-js":["/component---cache-caches-gatsby-plugin-offline-app-shell-js-258fa972005c75a2a109.js"],"component---src-pages-404-tsx":["/component---src-pages-404-tsx.4b20f8dadfa146d0f95d.css","/component---src-pages-404-tsx-db046304e34e9a4e982b.js"],"component---src-pages-about-development-tsx":["/component---src-pages-about-development-tsx.4c5b5dd941fb0f6fd929.css","/component---src-pages-about-development-tsx-a805dcaba6372bd3fd34.js"],"component---src-pages-about-index-tsx":["/component---src-pages-about-index-tsx.a9a4b7f951b698486005.css","/component---src-pages-about-index-tsx-d5e998d3f688352286e1.js"],"component---src-pages-index-tsx":["/component---src-pages-index-tsx.49dafffcf9ae0c5f0d9f.css","/component---src-pages-index-tsx-6cc2ff789de11ec327f6.js"],"component---src-pages-search-tsx":["/component---src-pages-search-tsx.f915457cd8b05c27e895.css","/component---src-pages-search-tsx-a51f99760cb0d47808e2.js"],"component---src-pages-specialities-tsx":["/component---src-pages-specialities-tsx.fc62cf637c7ba1e609e7.css","/component---src-pages-specialities-tsx-90b8d3e5a5a3bff52a17.js"],"component---src-pages-topics-tsx":["/component---src-pages-topics-tsx.dfa0c1027e3cbeb11bdc.css","/component---src-pages-topics-tsx-960f75c13acbee11c017.js"],"component---src-pages-whats-new-tsx":["/component---src-pages-whats-new-tsx.7f7660f22ce5e07ac85a.css","/component---src-pages-whats-new-tsx-f78b713a66b42005fd9f.js"],"component---src-templates-chapter-level-1-chapter-level-1-tsx":["/component---src-templates-chapter-level-1-chapter-level-1-tsx.1a16ce552cccd7e50c41.css","/component---src-templates-chapter-level-1-chapter-level-1-tsx-0a03778bb80ba711929e.js"],"component---src-templates-chapter-level-2-chapter-level-2-tsx":["/component---src-templates-chapter-level-2-chapter-level-2-tsx.d09ef71dfbb262c31a03.css","/component---src-templates-chapter-level-2-chapter-level-2-tsx-3330d13663fb7ba90e1c.js"],"component---src-templates-speciality-speciality-tsx":["/component---src-templates-speciality-speciality-tsx.fc62cf637c7ba1e609e7.css","/component---src-templates-speciality-speciality-tsx-3357943d471e489a1b5f.js"],"component---src-templates-topic-topic-tsx":["/component---src-templates-topic-topic-tsx.afc04214919e241c3c2e.css","/component---src-templates-topic-topic-tsx-f17fe03d0b9a54a96aea.js"]};/*]]>*/</script><script src="../../../../polyfill-2cb897c2a056d28c9332.js" nomodule=""></script><script src="../../../../component---src-templates-chapter-level-2-chapter-level-2-tsx-3330d13663fb7ba90e1c.js" async=""></script><script src="../../../../0ad1f03a47300760909b2ab244b34289611800a7-fa70b32ffeeba2673019.js" async=""></script><script src="../../../../b95b9d9ffa67e6928854e772968693a58a7317d7-a9e1e5c953d4eee49b87.js" async=""></script><script src="../../../../app-53a71c38b210970893c4.js" async=""></script><script src="../../../../framework-34da02e39e1f104d9937.js" async=""></script><script src="../../../../webpack-runtime-28c424ef71f39faedaf0.js" async=""></script></body></html>